Sage Journals: Discover world-class research

Abstract

PTEN-induced kinase 1 (PINK1)-related Parkinson's disease (PD) is traditionally considered a rare autosomal recessive form of early-onset PD (EOPD), lacking classical Lewy body pathology. However, this characterization underestimates and oversimplifies PINK1-PD, largely due to a lack of extensive studies in diverse ethnic populations. This review and meta-analysis explores considerable variations in PINK1 variant rates and the wide heterogeneity influenced by patient- and variant-specific factors, delineating a more precise disease profile. Our findings reveal that PINK1-PD is more common than previously thought, with geographic ‘hotspots’ where up to 9% of EOPD cases are linked to PINK1 variants, including the pathogenic p.Leu347Pro variant affecting 1 in 1300 West Polynesians. Homozygous PINK1-PD typically manifests around age 35, predominantly affecting the lower limbs, with an excellent response to levodopa. Heterozygous PINK1-PD presents an ‘intermediate’ phenotype, with a later onset age (around 43 years) than homozygous PINK1-PD but earlier than idiopathic PD (typically after age 65). The severity of the phenotype is influenced by variant zygosity and pathogenicity, interacting with genetic and environmental factors to push some individuals beyond the disease threshold. Notably, females with PINK1-PD have earlier onset age than males, particularly in homozygous cases and when variants occur in the first half of PINK1's kinase domain. Contrary to traditional views, α-synuclein pathology is present in 87.5% of PINK1-PD postmortem cases across ages and variants. We challenge conventional views on PINK1-PD, highlighting distinct phenotypes influenced by zygosity, sex, and a role for α-synuclein pathology, urging for increased recognition and research of this not-so-rare disease.

Plain language summary

Variants in the gene PTEN-induced kinase 1 (PINK1) cause early onset Parkinson's disease, a form traditionally thought to be rare and lacking usual brain changes seen in typical Parkinson's. However, this may underestimate and oversimplify the condition, especially for certain ethnic groups. We analyzed 120 studies of 743 patients with PINK1-related Parkinson's, finding that in some areas, up to 9% of early-onset Parkinson's is due to PINK1 variants. One specific damaging variant, p.Leu347Pro, affects about 1 in 1300 West Polynesians, exceeding the threshold for a rare disease. People with PINK1 Parkinson's experience symptoms around age 35, mostly affecting their legs, and they respond well to the medication levodopa. Although it was thought two copies of a PINK1 variant were required to develop disease, those with one copy show similar Parkinson's symptoms but with a later onset, around age 43 (still earlier than typical Parkinson's which generally starts after age 65). Women with PINK1 Parkinson's tend to show symptoms earlier than men. This difference is more pronounced in those with two copies of the variant and when the variant occurs in a specific part of the PINK1 gene. Post-mortem studies reveal that a protein called α-synuclein, usually associated with typical Parkinson's, is present in 87.5% of PINK1 Parkinson's cases, highlighting it's involvement in this form of disease. Our study challenges the conventional understanding of PINK1 Parkinson's, describing unique characteristics dependent on the variant type. Given its higher rates in some regions, we call for greater recognition and research into PINK1-linked Parkinson's disease.

Keywords

Parkinson's disease mutation ethnicity prevalence age of onset alpha-synuclein meta-analysis sex pathogenicity phenotype

Introduction

While classic Parkinson's disease (PD) is primarily an affliction of the aged population, characterized by bradykinesia, tremor, rigidity, and postural instability, individuals with early onset PD (EOPD) are symptomatic before 50 years of age and can carry these devastating effects with them for the majority of their lives.^1,2 EOPD comprises approximately 10% of 8.5 million individuals worldwide living with PD,^3,4 and the second most common cause is variants in the gene PTEN-induced kinase 1 (PINK1).^2,5 Some similarities emerge across previously reported patients with PINK1 variants. Typically, individuals present around 30–40 years of age with PD symptoms predominantly in the lower limbs, an excellent prolonged response to levodopa pharmacotherapy (though often developing drug-related dyskinesia) and slow disease progression.^6–9 This characteristic phenotype bears striking dissimilarities to typical late onset, rapidly deteriorating, idiopathic PD.

In the present review and meta-analysis, we performed a systematic search of the current literature on PINK1 variants in PD to investigate the specific factors at play in this under-researched disease. While most reports quote PINK1 PD as a rare homozygous recessive disease, the fluctuation in these observed rates suggests regional variability, with the population rates of PINK1 variants ranging between 1–9% of all EOPD cases.^2,6,9–11 We debate the role that zygosity, ethnicity, sex and other genetic and environmental factors play in manifesting this typical phenotype and age of onset, positing that it is more beneficial to consider the distinct profile of PINK1 PD as a separate spectrum of disease. Lastly, we explore the association between PINK1 PD and α-synuclein (α-Syn) pathology.

Methods

Our meta-analysis included 120 studies that met our criteria. A full description of the methodology is available in Supplemental Information 1. We performed a systematic search using PubMed, Scopus, Web of Science (All Databases), and Google Scholar databases for relevant articles published before 31 August 2023. We used the search terms “Parkinson's disease”, “PINK1” and one of “Europe*”, “Asia*”, “Africa*”, “Latin*” or “Polynesia*”. The total number of records returned was 415, from which 145 duplicates were removed. The remaining 270 records were screened to exclude 177 studies written in a language other than English or if they were not primary articles studying human PINK1 PD patients (investigative studies screening for PINK1 variants in patients (even if not detecting any present) were included). The remaining 93 reports were all retrieved and subsequently assessed to determine if they classified the relevant patient ethnicity, deriving 75 included articles.^5,12–85 An additional 45 studies were included outside of the systematic search, as they either investigated multiple ethnicities across the described categories or were found separately throughout the literature scope (a portion through the Human Gene Mutation Database^®).^{6,9,11,86–127} These studies met the criteria for inclusion and thus were included in the following analysis.

All variants were reported unless they were described as a benign common polymorphism. For each individual, available patient PINK1 variant information was recorded (specific variant, zygosity, reported pathogenicity), as well as their available demographic information (age at disease onset, age at death (if applicable), disease duration, sex, ethnicity (with any ancestry information), symptomatology, family history (including whether family carried the same variant or not), and any family consanguinity). Corresponding authors were contacted for reports with missing information, and all data was retrieved while maintaining patient consent and confidentiality. For consistency, we maintained each report's prediction of variant pathogenicity (even if it was contradicted in other studies) and included the predictions of gnomAD and ClinVar pathogenicity data to compare.

For meta-analysis, all normality and variance tests were performed in RStudio. To assess for normality, the Shapiro-Wilk test was chosen as it is more sensitive to deviations from normality and suitable for smaller sample sizes (our overall cohort was large, however, some sub-groups assessed were small (n < 30)). Though the main pool of patient data was the same, each group was assessed for normality for each pairwise comparison as the patient groups varied in size. If p ≤ 0.05 for the Shapiro-Wilk test (rejecting the null hypothesis indicating a non-normal distribution), the Wilcoxon rank-sum test (for dependent groups) or Mann-Whitney U test (for independent groups) was chosen for comparison analysis. If p > 0.05 for the Shapiro-Wilk test (failing to reject the null hypothesis and indicating the data does not significantly deviate from a normal distribution), the groups were tested for equality of variance using Levene's test. If p ≤ 0.05 for Levene's test (rejecting the null hypothesis indicating a significant difference in variances between the groups), Welch's t-test was chosen for comparison analysis. If p > 0.05 for Levene's test (failing to reject the null hypothesis and indicating no significant difference in variance between the groups), Student's t-test (for independent groups) or paired t-test (for dependent groups) was chosen for comparison analysis. All comparisons were performed in RStudio and Microsoft Excel using a two-tailed distribution to investigate differences in either direction. The significance threshold for all pairwise comparisons used was set at p < 0.05.

Results and discussion

We found partial information for 743 individual PINK1 cases (see Supplemental Information 1). A total of 280 patients were found with the minimum requirement for analysis (potentially pathogenic variant and at least one of sex or age at onset data). Their data are summarized in Table 1 (refer to Supplemental Information 3 for individualized data). For analysis, compound heterozygous variants were grouped with homozygous variants as they are generally accepted to have the same effect by mutating both alleles. Individualized age at onset data was found for 235 cases and individualized sex data was found for 252 cases, however it must be noted that specific variants were often reported inconsistently, and in single cases or low numbers overall. As such, our analyses associating observed differences in specific variants are based on the available data and highlight the need for consistent PINK1 PD testing and reporting.

Table 1.

Summary of PINK1 variants and case data for meta-analysis.

Amino acid change	n	Reported pathogenicity from reference(s)	gnomAD and ClinVar pathogenicity prediction	Zygosities	Age at onset or diagnosis (years)	Disease duration at publication or last examination (years)	Sexes	Ethnicity/ ethnicities	Reference
Leu31Ter	2	Abs	Abs	Hom	33, 36	6		Turkish	Lohmann et al., 2012⁴⁶
Gly43Arg	1	US	US	Het			F	Japanese	Hayashida et al., 2021*¹²⁴
Arg58_Val59insGlyArg	5	LP, US	US	Hom, Het	39		2M, 3F	Japanese, Korean	Hayashida et al., 2021*¹²⁴, Youn et al., 2019⁵⁸
Leu63=	4	Abs	B	Het	20, 23, 25, 27		1M, 3F	Jordanian	Myhre et al., 2008*⁸⁸
Ala78Val	2	LP	Abs	Het	39	21	1M, 1F	Japanese	Hayashida et al., 2021¹²⁴, Kumazawa et al., 2008⁹⁰
Arg88Trp	1	LP	Abs	Het	18	0	1F	Indian	Bandla et al., 2022*⁹⁶
Ser123Ter	1	US	Abs	Het	34	5	1F	Indian (South)	Kukkle et al., 2022¹⁸
Gln126Pro	3	P, Abs	LP	Hom	36, 40, 55	6, 11, 12	1M, 2F	German, Italian (South)	Prestel et al., 2008*¹⁰⁸, Scornaienchi et al., 2012¹⁶
Gln129fsTer157	11	LP	Abs	Hom			8M, 3F	Tunisian (Arab-Berber descent)	Ishihara-Paul et al., 2008*⁹¹; Nishioka et al., 2009¹³
Gln129Ter	6	LP	LP	Hom, Het	38		3M, 3F	Tunisian (Arab-Berber descent)	Ishihara-Paul et al., 2008*⁹¹; Nishioka et al., 2009¹³
Pro142Leu	1	LP	US	Het			F	Japanese	Hayashida et al., 2021*¹²⁴
Gly163ValfsTer22	2	P	Abs	Hom	38, 40	7, 12	1M, 1F	Iranian	Soudyab et al., 2022*⁸⁹
Ala168Pro	3	P, Abs	P, LP	Hom	30, 38, 39	14, 32, 44	2M	Italian (Sicilian), Polish	Bonifati et al., 2005⁶, Milanowski et al., 2021⁵, Valente et al., 2004a⁹
Lys186Asn	2	LP	US, B	Het	31, 36	9	1M, 1F	Polish, Serbian	Djarmati et al., 2006*¹⁰¹, Koziorowski et al., 2013⁴⁰
Gly193Arg	1	Abs	Abs	Het	37	18	1M	Taiwanese	Weng et al., 2007*¹¹⁰
Pro196Leu	1	LP	US	Het	45	15	1M	Italian (Sicilian)	Bonifati et al., 2005*⁶
Pro196GlnfsTer25	1	Abs	Abs	Het	58	16	1F	Japanese	Kumazawa et al., 2008*⁹⁰
Arg207Gln	2	LB, US	US	Het	24, 71	1, 19	2M	European/American (Ashkenazi, Russian), Italian (South)	Benitez et al., 2016²⁹, Scornaienchi et al., 2012¹⁶
Pro209Ala	1	Abs	Abs	Het	30	7		Taiwanese	Lee et al., 2009⁴¹
Pro209Leu	1	LP	US	Het	42	15	1M	Serbian	Djarmati et al., 2006*¹⁰¹
Ala217Asp	7	LP	P	Hom	9, 13, 13, 14, 14, 27, 29	7, 9, 22, 25, 30, 33	3M, 2F	Moroccan (French North African descent), Sudanese (North)	Leutenegger et al., 2006*⁸⁷, Norman et al., 2017⁴⁹
Asn223LysfsTer12	2	P	Abs	Hom	41, 44	6, 12	2M	Iranian	Soudyab et al., 2022*⁸⁹
Met237Val	1	LP	US	Het	31	31	1M	Dutch	Macedo et al., 2009*¹⁰⁶
Glu240Lys	1	P	Abs	Hom	38	10	1M	Sri Lankan	Ibáñez et al., 2006*⁹⁵
Arg246Gln	1	LP	US	Het	43	14	1M	Indian	Biswas et al., 2010²⁴
Arg246Ter	6	P, Abs	P	Hom	24, 25, 25, 30, 33, 33	17, 17, 18, 21, 22	6M	Chinese/Malaysian/Indian, Japanese, Jewish-Iraqi, Israeli	Ephraty et al., 2007⁹⁴, Hatano et al., 2004¹⁰³, Tan et al., 2006¹⁹
Tyr258Ter	4	Abs	P	Hom	37, 45, 47, 51	30	2F	Chinese/Malaysian/Indian, South African (Indian descent)	Keyser et al., 2009³⁷, Tan et al., 2006¹⁹
Gln267Ter	1	P	Abs	Hom	31	16	M	Indian (North)	Halder et al., 2015³⁶
His271Gln	2	P	P	Hom	23	15	1M, 1F	Japanese	Hatano et al., 2004*¹⁰³, Hayashida et al., 2021¹²⁴
Arg276Gln	6	P, LP	US, B	Het	28, 38, 39, 41, 48, 48	1, 5, 7, 13, 13, 15	5M, 1F	Indian	Biswas et al., 2010²⁴, Halder et al., 2015³⁶
Leu278Val	1	P	Abs	Het	40	4	F	Chinese	Guo et al., 2010²⁵
Arg279Cys	3	LP, US	US	Hom, Het	50		3M	Japanese, Korean	Hayashida et al., 2021*¹²⁴, Youn et al., 2019⁵⁸
Ala280Thr	1	LP	US	Het	45		F	Chinese/Malay/Indian	Tan et al., 2006¹⁹
Val285Met	1	P	US	Het			F	Japanese	Hayashida et al., 2021*¹²⁴
Asp297MetfsTer22	1	Abs	Abs	Hom	10	15	F	Greek	Kumazawa et al., 2008*⁹⁰
Pro305Ala	1	LP	US	Het	30		F	South African (Black Xhosa)	Keyser et al., 2010³⁸
Arg312Gln	2	US	US	Het	44		1M, 1F	Chinese, Japanese	Hayashida et al., 2021*¹²⁴, Tay et al., 2023²⁰
Thr313Met	5	LP, Abs	P	Hom, Het	30, 32, 33, 34, 50	2, 8, 12	4M	Japanese, Malaysian, Saudi Arabian, Saudi Arabian (Mecca)	Al-Mubarak et al., 2015²⁷, Chishti et al., 2006⁹⁹, Kumazawa et al., 2008⁹⁰, Tay et al., 2023²⁰
Val317Ile	1	US	US	Het	51	26		English	Abou-Sleiman et al., 2006*¹²¹
Met318Leu	3	LP	US	Het	47, 48, 65	9, 19	1M, 1F	Italian (South Tyrolean), USA/Caucasian	Brooks et al., 2009⁹³, Djarmati et al., 2006¹⁰¹
Ala339Ser	2	US	Abs	Hom	39, 55	19, 34	1M, 21F	European-American/Caucasian (“American”), European-American (Irish, Scottish, English, German)	Benitez et al., 2016²⁹
Ala339Thr	1	LP, US	LP, US	Het	64	14	M	English	Abou-Sleiman et al., 2006¹²¹; Gandhi et al., 2006¹¹⁸
Met341Ile	3	US	US, LB	Het	35, 39	11, 14	F	Japanese, Taiwanese	Hayashida et al., 2021*¹²⁴, Lee et al., 2009⁴¹
Met342Leu	1	US	US	Hom	45		F	Korean	Youn et al., 2019⁵⁸
Met342Val	2	Abs	US	Het	49, 53	4, 12	1M, 1F	Japanese	Kumazawa et al., 2008*⁹⁰
Leu347Pro	29	P, Abs	P	Hom	18, 19, 23, 24, 25, mid 20's, 26, 27, 27, 30, 30, 32, 32, 33, 34, 36, 37, 40, 40, 41, 42, 44, 48, 48, 50, 51, 55, 63, 67	0.5, 3, 3, 4, 6, 9, 9, 6–10, 10, 10, 12, 12, 14, 14, 11–15, 16, 18, 18, 19, 19, 19, 16–20, 21, 22, 23, 23, 31–35, 31–35	14M, 14F	Chamorro, Filipino, Indonesian/Malaysian, Malaysian, Samoan, Spanish, Tongan	Caritativo et al., 2023¹¹³; Doostzadeh et al., 2007¹²⁰, Hatano et al., 2004¹⁰³, Morales-Briceno et al., 2022⁴⁷, Patel et al., 2021¹², Rogaeva et al., 2004¹¹, Steele et al., 2015*⁸⁶, Tan et al., 2020⁵³, Tay et al., 2023²⁰, Tejera-Parrado et al., 2020⁵⁴
Val350Leu	2	US	Abs	Het	16, 43		2M	Chinese	Tay et al., 2023²⁰
Asn367Ser	2	US	Abs	Hom	61, 77	9, 17	2M	European-American (English), European-American (Swedish, Irish, English)	Benitez et al., 2016²⁹
Ile368Asn	3	P	Abs	Hom	28, 33, 44	43, 44	2M, 1F	Polish	Ando et al., 2017*¹²⁶; Koziorowski et al., 2013⁴⁰, Milanowski et al., 2021⁵
Ala383Thr	2	LP, LB	US, LB	Het	36, 58	8, 9		English, Moroccan	Abou-Sleiman et al., 2006¹²¹, Ibáñez et al., 2006⁹⁵
Gly386Ala	1	P	Abs	Hom	21	47	F	French	Ibáñez et al., 2006*⁹⁵
Cys388Arg	5	P	LP	Hom, Het	39, 44, 54, 55	2, 5, 10, 16	1M, 4F	Japanese	Hayashida et al., 2021¹²⁴, Kumazawa et al., 2008⁹⁰, Li et al., 2005*¹⁰⁵
Gly395Ser	1	US	US	Het	45		M	Chinese	Tay et al., 2023²⁰
Arg407Gln	4	LP	US	Het	40, 47, 54	3, 7, 19	4M	Chinese, Japanese, Taiwanese	Fung et al., 2006³⁵, Hayashida et al., 2021*¹²⁴, Guo et al., 2010²⁵
Gly408AlafsTer6	2	P	Abs	Hom	36, 38	6, 9	1M, 1F	Iranian	Soudyab et al., 2022*⁸⁹
Gly409Arg	2	LP	Abs	Hom	50, 66		1M, 1F	Saudi Arabian	Al-Mubarak et al., 2015²⁷
Gly409Val	1	P	Abs	Hom	32	30	M	French	Ibáñez et al., 2006*⁹⁵
Gly411Ser	10	LP, US	US, LB, B	Het	13, 26, 36, 39, 43, 43, 54, 60, 62, 63	2, 6, 10, 13, 15, 16, 34	3M, 2F	Australian (likely European descent), Irish/German, Norwegian, Polish, Swedish	Koziorowski et al., 2013⁴⁰, Mellick et al., 2009¹⁰⁷, Puschmann et al., 2017¹²², Toft et al., 2007²⁶, Zadikoff et al., 2006*¹¹²
Pro416Leu	2	LP	Abs	Hom, Het	48, 52	4, 8	1M, 2F	Turkish	Lohmann et al., 2012⁴⁶
Pro416Arg	1	P	Abs	Hom	23		M	Jordanian	Myhre et al., 2008*⁸⁸
Glu417Gly	1	P	Abs	Hom	33	8	F	Japanese	Hatano et al., 2004*¹⁰³
Tyr431His	1	P	Abs	Het	59	21	F	English	Abou-Sleiman et al., 2006¹²¹; Gandhi et al., 2006¹¹⁸
Trp437Ter	9	LP	P	Hom, Het	22, 29, 30, 32, 38, 45, 48, 53, 77	5, 7, 20, 20, 20, 23, 29, 29, 28	4M, 5F	Italian (Sicilian), Italian (South), Spanish	Criscuolo et al., 2006¹¹⁴; Bonifati et al., 2005⁶, Scornaienchi et al., 2012¹⁶, Valente et al., 2001¹²⁵; Valente et al., 2004b¹¹⁵
Trp437Arg	1	Abs	Abs	Hom	19	21	F	Turkish	Kumazawa et al., 2008*⁹⁰
Gly440Glu	2	LP	Abs	Hom			2F	Tunisian (Arab-Berber descent)	Ishihara-Paul et al., 2008*⁹¹; Nishioka et al., 2009¹³
Gly448Arg	1	LB	Abs	Het	50		F	Chinese	Hua et al., 2022*¹⁰⁴
Asn451Ser	1	LP	Abs	Het	58	10	M	English	Abou-Sleiman et al., 2006¹²¹; Gandhi et al., 2006¹¹⁸
Gln456Ter	21	P, LP, Abs	P	Hom, Het	16, 24, 27, 34, 35, 36, 37, 38, 39, 39, 41, 47, 53, 53, 61	2, 3, 6, 7, 9, 11, 11, 13, 18, 19, 20, 22, 24, 30, 34	9M, 7F	German, Italian, Italian (Sicilian), Italian (South), Polish, Tunisian (Arab-Berber descent)	Bonifati et al., 2005⁶, Hedrich et al., 2006¹⁵, Ibáñez et al., 2006⁹⁵, Ishihara-Paul et al., 2008⁹¹; Nishioka et al., 2009¹³, Milanowski et al., 2021⁵; Siuda et al., 2014⁵¹, Scornaienchi et al., 2012¹⁶, Smaoui et al., 2012⁵⁰, Zadikoff et al., 2006¹¹²
Val482Met	2	LB	US	Het			1M, 1F	Japanese	Hayashida et al., 2021*¹²⁴
Leu489Pro	2	P	Abs	Hom	40, 60	14, 35	2F	Malaysian (Indian descent)	Lim et al., 2021⁴⁴, Tay et al., 2023²⁰
Arg492Ter	3	P, Abs	P	Hom, Het	19, 40, 42	3, 31	3F	Chinese, Dutch, Taiwanese	Chen et al., 2022⁹⁸, Macedo et al., 2009¹⁰⁶, Weng et al., 2007*¹¹⁰
Pro498Leu	1	LP	Abs	Het	58	4	M	Norwegian	Toft et al., 2007²⁶
Ala504Val	1	US	Abs	Het	38		M	Indian	Tay et al., 2023²⁰
Leu519fsTer522	1	P	Abs	Hom	40	7	M	Algerian	Ibáñez et al., 2006*⁹⁵
Lys520ArgfsTer3	1	P	Abs	Hom	28	5	M	Chinese (Han)	Wang et al., 2018⁵⁷
Asn521fs	1	LP	Abs	Hom	19	8	M	Chinese	Chen et al., 2020³¹
Asn521ThrfsTer40	1	LP	Abs	Hom	40		F	Chinese	Chen et al., 2022*⁹⁸
Asp525fsTer562	1	P	Abs	Hom	28	7	F	Italian (Sicilian)	Bonifati et al., 2005*⁶
534_535insGln	2	LP	Abs	Hom, Het	25, 32	23, 25	1M, 1F	Italian	Klein et al., 2005³⁹
Gln534Lys	1	LP	US	Het			M	Japanese	Hayashida et al., 2021*¹²⁴
Ser535Leu	1	P	Abs	Het	28		M	Polish	Koziorowski et al., 2013⁴⁰
Thr538Pro	2	LP	US	Hom, Het			1M, 1F	Japanese	Hayashida et al., 2021*¹²⁴
Leu539Phe	1	LP	Abs	Hom	54	4	M	Moroccan	Ben El Haj et al., 2016*⁹⁷
Asn542Ser	1	Abs	Abs	Het	69	7	F	Japanese	Kumazawa et al., 2008*⁹⁰
Cys575Arg	1	LP	Abs	Het	64	7	M	English	Abou-Sleiman et al., 2006¹²¹; Gandhi et al., 2006¹¹⁸
Cys125Gly/Gln456Ter	1	P	Abs/P	C-Het	41	30	F	Italian	Ibáñez et al., 2006*⁹⁵
Gln239Ter/Arg492Ter	4	P	Abs/P	C-Het	17, 18, 18, 19	20, 22, 24, 25	4F	Taiwanese	Hatano et al., 2004¹⁰³, Weng et al., 2007¹¹⁰
Lys24fsTer54/Cys549fsTer553	3	P	Abs	C-Het	31, 40, 52	31, 36, 38	2M, 1F	French	Ibáñez et al., 2006*⁹⁵
Glu240Lys/Leu489Pro	1	Abs	Abs	C-Het	30	43		Canadian	Rogaeva et al., 2004¹¹
Ala244Gly/Val317Ile	1	LP	Abs/US	C-Het	67	10	F	Italian	Gelmetti et al., 2008*¹⁰²
Arg279His/Ser284=	1	LP	US/LB	Het	49	6	M	Italian	Klein et al., 2005³⁹
Ala340Ser/Asn521Thr	1	B	Abs/B, LB	C-Het	36		M	Jordanian	Myhre et al., 2008*⁸⁸
Leu369Pro/Arg492Ter	2	P	Abs/P	C-Het	29, 34	7, 9	1M, 1F	French	Ibáñez et al., 2006*⁹⁵
Gly386Ala/Trp437Ter	1	Abs	Abs/P	C-Het	32		F	European or Chinese	Cobb et al., 2009*¹⁰⁰
Asp391=/Ser419Pro/Asn521Thr	2	P (S419P)	LB/Abs/LB	C-Hom	35, 36		2F	Jordanian	Myhre et al., 2008*⁸⁸
Arg492Ter/(exon 7 splicing)	1	P	P	C-Het	15	6	F	Chinese	Li et al., 2020⁴²; Li et al., 2021⁴³
Cys92Phe/Arg464His	1	Abs	Abs/US	C-Het	37	23	F	Italian	Valente et al., 2004a*⁹
Leu77Pro/exon 4-5 del	1	P	Abs	C-Hom/Het	44	36	F	Norwegian	Nybø et al., 2020*¹¹⁷
c.1124-2A > T	2	P	Abs	Hom	37, 38	9, 10	2M	Iranian	Soudyab et al., 2022*⁸⁹
IVS5-4C > T (intronic)	1	LB	Abs	Het	40	2	F	Italian (Sicilian)	Bonifati et al., 2005*⁶
IVS3 + 38_+40delTTT (intron 3)	1	US	Abs	Het	39	24	F	Italian (Sicilian)	Bonifati et al., 2005*⁶
c.959 + 1G > A (intron 4)	1	LP	Abs	Hom	26	7	F	Indian (South)	Kukkle et al., 2022¹⁸
Exon 1 del	5	P, Abs	Abs	Hom, Het	28, 37, 38, 45, 45		4M, 1F	Brazilian, Chinese	Chen et al., 2022*⁹⁸, Moura et al., 2012⁴⁸
Exon 2 del/exon 2–4 del	1	Abs	Abs	C-Het	25			Iranian (Balochi)	Darvish et al., 2013¹⁴
Exon 3–8 del	1	P	Abs	Het	44	6	F	Chinese	Guo et al., 2010²⁵
Exon 4–8 del	3	Abs	Abs	Hom	11, 15, 21	4, 6, 20	2M, 1F	Sudanese	Cazeneuve et al., 2009³⁰
Exon 6–8 del	1	Abs	Abs	Hom	38	25	F	Japanese	Li et al., 2005*¹⁰⁵
Exon 7 del	1	Abs	Abs	Hom	24	19	F	Brazilian	Camargos et al., 2009¹⁷
Exon 7 del/c.1488 + 1G > A	6	P	Abs	C-Het/Hom	14, 27, 31, 31, 34, 45	3, 8, 9, 9, 22, 34	3M, 3F	Spanish	Samaranch et al., 2010*¹¹⁶

Ins: insertion; fs: frame shift; del: deletion; P: pathogenic; LP: likely pathogenic; US: uncertain significance; LB: likely benign; B: benign; Abs: absent from reference or database; Hom: homozygous; Het: heterozygous; C-: compound; M: male; F: female

Populations with the highest PINK1 variant rates are overlooked

From our systematic search, we found 279 cases with ethnicity information (Figure 1). Most reports of PINK1 variants were found in Asian and European patients (35.13% and 31.54%, respectively), followed by Africa (17.92%). PINK1 variants were most frequently reported in cases originating from Japan (12.19%), Italy (11.83%), and Tunisia (8.96%). However, when the case frequency was normalized to the population of the country of origin,¹²⁸ the countries with the highest frequency and incidence were Tonga (5.61E-05, 1:17,810), Guam (2.33E-05, 1:42,944) and Samoa (1.35E-05, 1:74,127) (Figure 1(b)).

Figure 1.

Case frequency of PINK1 variants across countries (n = 279). Overall case frequency by (a) study location, and (b) ethnic origin with frequency normalized to country populations (using World Bank Group data¹²⁸) with the top three countries enlarged. Case frequency by specific variant for (c) North and South America, (d) Australia and Oceania, (e) Africa, (f) Europe, and (g) Asia. Continents are not to scale between each map, but circles are to scale and represent n. Circles are in the country center and do not represent any specific region. Maps are configured to show only the countries with reported cases corresponding to the continent(s).

Specifically, the most frequently reported variants were p.Leu347Pro (pathogenic, n = 29), p.Gln456Ter (pathogenic, n = 21), and p.Gln129fsTer157 (uncertain significance, n = 11) (Figure 1(c)–(g)). Of the p.Gln456Ter cases, 71.43% were of European descent (Italian, German, Polish, English), with the remaining cases being of African descent (Tunisian). Of the p.Leu347Pro cases, 51.72% were of Asian descent (Filipino, Malaysian, Indonesian), another 44.83% were of Polynesian descent (Samoan, Tongan, Chamorro), and the remaining cases were European (Spanish). The worldwide allele frequency of p.Leu347Pro is 0.0016%,¹²⁹ but the frequency across reported Polynesian, Pacific and Southeast Asian populations is as high as 0.33–5%.^11,12,86 Allele frequency here refers to the prevalence of an allele across all chromosomes in a population. The frequency of p.Leu347Pro for West Polynesia (Samoa, Tonga, Tokelau, and Niue) found in New Zealand by Patel et al. (2021) was 2.8%. Therefore, homozygous p.Leu347Pro variants may be implicated in approximately 1 in 1300 West Polynesians, increasing beyond the general definition of a rare disorder (approximately ≤1:2200).^12,130 One possible explanation for these high concentrations of PINK1 variants is their spread through specific migration routes and genetic bottlenecking.¹² Archaeological evidence suggests ancient Guam DNA likely descended from Filipino ancestry, and this DNA is closely linked to early Lapita individuals from Vanuatu and Tonga.¹³¹ The p.Leu347Pro variant thus could have been carried throughout Polynesia via a common founder population from Southeast Asia.¹³¹ In the case of p.Gln456Ter, no established theories link the Italian, German, Polish, English and Tunisian populations. Still, a migratory explanation could be plausible due to the proximity of the countries (Figure 1(e) and (f)).

Altered patterns of PINK1 inheritance

In genetic bottlenecking, there is often a founder effect where the reproductively isolated population is subject to decreases in genetic diversity and increases in consanguinity, the coupling of people who share a common ancestor.¹³² Consanguinity of people carrying PINK1 heterozygous variants increases the likelihood of offspring receiving both mutated copies and thus PD, as PINK1 follows an autosomal recessive inheritance pattern.^2,132 The highest rate of PINK1 variants (8.9%) was found in a multicontinental cohort of Parkin- and DJ-1-negative consanguineous families with autosomal recessive PD.¹⁰⁵ We identified several consanguineous families from Sudan, Jordan, and Iran with the same inherited PINK1 variants.^87–89 Homozygous variants p.Gln456Ter, p.Gln129Ter, p.Gln129fsTer157, and p.Gly440Glu (all pathogenic except p.Gln129fsTer157, a variant of uncertain significance) were found in 42 PD patients from 90 Tunisian consanguineous families.¹³ A consanguineous German family was found with a high carrier rate of the p.Gln456Ter variant (4 homozygous cases and 6 heterozygous possible cases from 20 family members),¹⁵ while two consanguineous Iranian families carried homozygous deletions of exon 4 or exon 5 (3 cases of each from 130 familial PD patients).¹⁴ Furthermore, two consanguineous families with a pathogenic Trp437Ter variant in PINK1 share a common haplotype, implying common ancestry and a potential founder effect.^114,115 In Italian patients with potentially pathogenic 534_535insGln variants, haplotype analysis indicated a plausible shared allele and a common founder.³⁹ In addition to published data, through additional requests for information we acquired consanguinity information for Polish p.Ile368Asn siblings (Zbigniew and Milanowski, 2024, personal communication), indicating consanguinity effects on PINK1-PD inheritance may be more common than reported.

The phenomenon of ‘pseudo-dominance’ has been observed when there is a high carrier rate of autosomal recessive disease variants, in which mating of an affected homozygote with an unaffected heterozygote mimics an autosomal dominant pattern (50% chance of offspring inheriting two mutated copies and thus PD, meaning ≥1 affected in 2 consecutive generations).^132,133 Affected heterozygote patients with consanguineous parents in Italy and the Philippines have been described as exhibiting inheritance patterns suggestive of autosomal dominant transmission.^6,113 The observed increase in ‘rare’ PINK1-positive Parkinson's disease (PD) cases within smaller consanguineous populations might be attributed to pseudo-dominance, as highlighted in the literature.^{6,16,90,113,114,122}

Ethnic bias in PD research and diagnosis

This trend of geographical PINK1 ‘hotspots’ suggests a potential underrepresentation of specific populations in genetic research, particularly those outside European or industrialized nations, which may reflect a systemic research bias. For example, the West Polynesian ‘hotspot’ of pathogenic p.Leu347Pro was reported in Samoan and Tongan PD patients living in New Zealand and no research has been conducted in their countries of origin thus far. In our analysis, we observed that the countries that the studies were conducted in did not always correspond to the ethnicity of the cases, indicating a potential deficiency of access or resources in the locations of interest.

Despite recognizing clear familial patterns of PINK1 PD, the discovery of numerous variants unique to individual cases prompts further investigation into the significance of variant-specific differences and their locations on the PINK1 gene. The lack of standardized guidelines for genetic PD panel testing and a tendency to overlook ethnicity—though European labs tend to offer more comprehensive panels—underscores the need for more inclusive research and testing protocols.^134,135 A recent large multi-center study advocating for better genetic testing reported low numbers of PINK1 PD but acknowledged that their cohort was predominantly European,¹³⁶ which shows that this lack of ethnic diversity is still a current issue requiring active and intentional attention. This can be achieved, however, as evidenced by an ongoing multi-center study working against this bias to characterize the global spectrum of monogenic PD.¹³⁷ Such measures are essential, especially for communities facing more significant healthcare challenges,^138–141 to ensure a broader representation and understanding of PINK1 PD's genetic landscape.

Homozygous PINK1 variants are not all created equal: different effects on protein function influence overall PD risk

Function and structure of PINK1

The PINK1 gene encodes the mitochondrial serine/threonine-protein kinase PTEN-induced kinase 1, which regulates mitophagy and is protective in oxidative stress-induced apoptosis.^142,143 Under normal circumstances, the PINK1 protein accumulates on the membranes of damaged mitochondria, recruiting and phosphorylating both ubiquitin and the Parkin protein to tag dysfunctional mitochondria for degradation.¹⁴⁴ A detailed discussion of PINK1's function in disease pathogenesis is available in Truban et al. (2017).¹⁴³ PINK1 has over 300 documented variants, from point variants to large gene rearrangements that can destabilize, truncate and inactivate the protein.^144,145 Not all variants are pathogenic, so it is essential to classify individual variants and their consequences to inform disease prognosis.¹⁴⁵

The PINK1 protein consists of 581 amino acids, with a kinase domain (located between amino acids 156–511), a region for outer membrane localization (amino acids 111–117), and a disordered region (amino acids 189–208).^146,147 Less well-defined regions include the early mitochondrial targeting sequence (between amino acids 1–80), subdivisions of the kinase domain called the N-lobe and C-lobe (between 156–340 and 320–511, respectively), and a C-terminal domain (between amino acids 486–581), though these are not established in protein databases and the literature varies.^{145,148–150}

Mechanisms of PINK1 pathogenesis

Loss of PINK1's kinase activity likely initiates PD pathogenesis, though the significance of variants outside this kinase domain remains unclear.^142,151,152 In vitro cell experiments demonstrate many mechanisms by which PINK1 variants may disrupt normal function depending on their location. Variants p.Glu240Lys (uncertain significance), p.Gly309Asp (uncertain significance) and p.Leu489Pro (likely pathogenic) spread wide across the kinase domain appear to destabilize the PINK1 protein and disrupt kinase activity in transfected human or animal cells, with p.Gly309Asp specifically disrupting adenosine diphosphate binding required for normal mitochondrial regulation.^115,153 Cells from patients with p.Val170Gly variants (uncertain significance, absent from the ClinVar database), located relatively early along the PINK1 kinase region, show swollen mitochondria and dysregulated mitochondria function via the altered activity of respiratory chain enzyme complexes.¹⁵⁴ Patient cells with variants near the end of the kinase domain also show varying effects; p.Trp437Ter (pathogenic) downregulates expression of the S100A4 calcium-binding protein in mitochondria, leading to neuronal cell death,¹⁵⁵ while p.Gln456Ter (pathogenic) patient cells show decreased ATP levels, resulting in impaired bioenergetic function.¹⁵⁴ Overall, there is not one common mechanism through which pathogenic PINK1 variants initiate PD-related pathogenesis. Instead, a varied spectrum of alterations to mitochondria and cell activity may disrupt PINK1 function and cause or contribute to disease.¹²²

A spectrum of PINK1 pathogenicity

One systematic analysis assessed 50 missense PINK1 variants and re-classified their pathogenicity using published clinical, population-wide and functional evidence, combined with additional functional experiments.¹⁴⁵ In standard terminology, variants are categorized depending on the available evidence ranging from ‘benign’ or ‘likely benign’ to ‘likely pathogenic’ or ‘pathogenic’ or as a ‘variant of uncertain significance’, considering the strength of their segregation with the disease, minor allele frequency, and homozygosity in controls.¹⁴⁵ From the systematic analysis, most pathogenic variants were located in the kinase region,¹⁴⁵ paralleling our present data showing approximately 90% of pathogenic or likely pathogenic variants lay within this domain (Figure 2), reiterating the importance of the kinase in normal PINK1 function. The specific variant had a clear effect on mitophagy; most variants classified as pathogenic or likely pathogenic caused a partial or total reduction of normal PINK1-related mitophagy, indicating this loss of function is a primary mechanism of PINK1-related PD.¹⁴⁵

Figure 2.

Gene location of PINK1 point variants. Pathogenicity is described using available information from the original studies and the gnomAD/ClinVar database. Variants described using amino acid single letter codes (International Genetic System). Cross-hatched area: disordered region; italicized labels: regions not well-established in databases or literature; ML: region for outer membrane localization; MTS: mitochondrial targeting sequence.

Only some of the variants found in our systematic search were included in the large-scale analysis by Ma et al. (2021).¹⁴⁵ Still, those assessed were all predicted pathogenic, likely pathogenic, or of uncertain significance. For variants predicted as being of uncertain significance, the functional assays indicate that though they do not entirely abolish kinase activity and mitophagy induction, these variants may still have a partial impact. For example, p.Pro296Leu and p.Gly309Asp, located in the gene region involved in ubiquitin binding, caused some disruption to mitophagy via the ubiquitin-PINK1-Parkin interaction and thus linked their position directly to their function.¹⁴⁵ Other variants reported as benign (p.Gln115Leu, p.Ala340Thr, and p.Asn521Thr) also reduced mitophagy induction, though not to a pathogenic level, suggesting a certain level of dysfunction is tolerated until a threshold at which pathogenesis is initiated.^145,156

Potential heterozygous PINK1 insufficiency

Our observation of PINK1 PD cases with non-benign heterozygous variants,^9,11,17,79 including when other risk genes (Parkin, DJ-1) are eliminated as a cause,^6,18,19 suggests that even one healthy allele may not meet the threshold for normal function. Haploinsufficiency is when the 50% level of function produced by the healthy gene copy is inadequate to produce the normal phenotype, which is classically a trait of autosomal dominant genes but can manifest in autosomal recessive genes.¹⁵⁶ In cell lines expressing one mutant copy of PINK1, there is decreased dopaminergic cell survival compared to the wild-type, and cell lines expressing two mutant copies have even lower survival.¹⁵⁷ Five PINK1 heterozygous variants (p.Tyr431His, p.Asn451Ser, p.Glu476Lys, p.Arg501Pro, and p.Cys575Arg, all variants of uncertain significance absent from the ClinVar database except the likely benign p.Glu476Lys) showed decreased mitochondrial membrane potential in vitro compared to wild-type PINK1.¹²¹ Therefore, variants in PINK1 may act as risk factors and increase the likelihood of more severe disease, with one mutant copy causing an ‘intermediate’ phenotype. Insufficient or excessive protein levels can alter the gene dosage stability, leading to detrimental effects.^158–160 Stochasticity in whether one healthy allele's function is above the threshold for initiating normal processes can differ from cell to cell, further complicating this balance.^{159,161–163} Heterozygous p.Gly411Ser variants (uncertain significance) in PINK1 decrease kinase activity in vitro compared to controls, and p.Gln456Ter (pathogenic) heterozygotes induce an inhibiting effect, not simply a loss-of-function.¹²² Thus, it is apparent that PINK1 variants and their zygosity differentially affect the normal protein function and contribute to an individual's overall PD risk in a variant-specific manner.

Heterozygous PINK1 brains show significant but subclinical signs of disease

One of the most repeated arguments for heterozygous PINK1 variant risk in PD is the observation of detectable differences in neuroimaging data compared to healthy controls. Structural abnormalities in PINK1 heterozygotes include increased substantia nigra echogenicity, which is indicative of higher iron levels and posited as a vulnerability marker for PD.^164,165 In animal studies, heterozygote PINK1 knockout mice were unable to produce long-term potentiation despite repetitive cortical inputs to striatal neurons, likely related to an observed decrease in striatal dopamine release.¹⁶⁶ In human patient positron emission tomography, PINK1 homozygotes exhibit a 60–85% decrease in 18-fluorodopa uptake in the caudate and putamen in comparison to controls, while heterozygotes exhibit a 20–30% decrease, indicating a subclinical but significant reduction of striatal dopamine storage capacity.^167,168 Another imaging study observed increased grey matter volume in the putamen and internal globus pallidus in those with heterozygous PINK1 variants compared to controls, suggesting this chronic dysfunction was a compensatory mechanism for dopaminergic denervation.¹⁶⁹ This ‘compensation’ hypothesis was corroborated with functional data by the same research group showing abnormal recruitment of the rostral supplementary motor areas and rostral dorsal premotor cortex in PINK1 heterozygotes when they completed a simple motor task.¹⁷⁰ These studies present an argument consistent with the idea of haploinsufficiency and a threshold for disease, in which heterozygous PINK1 can cause significant brain changes even if they are not detected in routine clinical observation. However, the same few studies are repetitively cited, and their arguments should be strengthened through newer studies in large cohorts.

Heterozygous PINK1 variants do not cause PD (alone)

Many support the dogma that PINK1 PD has autosomal recessive inheritance, arguing that there is little to no evidence for a causative role of heterozygous PINK1 variants.^{20,21,91,92,119,171,172} Meta-analyses in large PD case-control datasets detected no apparent association between heterozygous variants and PD in European^119,171 and North American populations.⁹³ Overall, heterozygous PINK1 variants appear to have a low (1–25%) penetrance¹⁵⁶ and might play only a minor susceptibility role in PD pathogenesis.⁹²

Our systematic search found 378 unaffected carriers reported with PINK1 variants (see Supplemental Information 4). Of these, 271 were classified as non-benign, and 90.04% carried heterozygous variants. Only 38 individuals carried variants predicted as pathogenic or likely pathogenic in EOPD by both the original report and gnomAD/ClinVar, and all were in heterozygous forms (p.Gln129Ter, p.Ala217Asp, p.Arg246Ter, p.Thr313Met, p.Leu347Pro, p.Trp437Ter, p.Gln456Ter, and p.Arg492Ter). Sixteen of these patients had sex recorded (6 males, 10 females), while 10 had a recorded age at observation that ranged from 39–86 years (mean ± SEM = 68.30 ± 4.65). Compared to affected patients, 15 cases carried these same variants in heterozygous forms (p.Thr313Met, p.Gln129Ter, p.Leu347Pro, p.Trp437Ter, p.Gln456Ter, and p.Arg492Ter). From 8 affected cases with age at onset data, the span was 34–77 years (mean ± SEM = 47.75 ± 6.05).

As the mean age of the unaffected carriers is over 50 years and higher than that of affected patients at onset, it could be assumed that these heterozygous variants do not pose a significant risk factor for developing EOPD in these individuals. Yet, affected and unaffected heterozygotes can present with identical PINK1 variants, even within the same family.^16,41,114 This questions whether other factors, aside from variant-specific differences and random chance, influence whether PINK1-related PD manifests.

Other variants of mitochondria function influence PINK1 disease

Research from the fruit fly Drosophila melanogaster has identified other mechanisms that may determine whether heterozygous PINK1 variants are significant enough to manifest disease by exacerbating deficiencies or compensating for them. A typical Drosophila melanogaster PINK1 mutant (PINK1^B9 is commonly used) shows muscle degeneration in the form of impaired flight and usually a mitochondrial deficiency in ATP production.^173–175 Alterations to mitochondria-related elements like transport, degradation, morphology, integrity, bioenergetic function, and antioxidant pathways can rescue the observed Drosophila melanogaster deficits via manipulation of kinases, proteases, signaling receptors, scaffolding proteins, vitamins, and detoxifying enzymes.^{173,176–186} Changes to gene expression or generation of these products from other variants or cellular signals could modulate the effect of a PINK1 variant, even if only slightly; it may be enough to tip the scale. Though performed in Drosophila melanogaster, these experiments provide plausible modifiers of PINK1 disease that may contribute to the varying presentations observed in heterozygous carriers.

Amino acid change	Zygosity	Sex	Ethnicity	Age at onset (years)	Disease duration (years)	Age at death (years)	α-syn	Location of a-synuclein	Symptomatology	Family history	Reference
Ala339Thr	Het	M	English	64	14	78	Y	Brainstem, neocortex	Early hypomimia, mild rigidity, tremor, later postural instability with frequent falls, very good L-dopa response, history of flat affect, cognitive decline after 7 years, rapid progression in 4 years	N	Gandhi et al., 2006¹¹⁸
Tyr431His	Het	F	English	59	21	80	Y	Brainstem, neocortex	Tremor predominant, early bradykinesia, rigidity, very good response to L-dopa, L-dopa induced dyskinesia and ON/OFF fluctuations, depression	N	Gandhi et al., 2006¹¹⁸
Asn451Ser	Het	M	English	58	10	68	Y	Brainstem, neocortex	Early hypomimia, bradykinesia, rigidity, minimal rest tremor, later postural instability, responded to L-dopa, L-dopa induced dyskinesia, depression	N	Gandhi et al., 2006¹¹⁸
Cys575Arg	Het	M	English	64	7	71	Y	Brainstem, neocortex	Early shuffling gait, tremor, rigidity, later hypophonia, very good response to L-dopa, history of paranoia and anxiety, confusion, visual hallucination, paranoia, cognitive decline after 5 years	N	Gandhi et al., 2006¹¹⁸
Leu77Pro/exon 4–5 del	Compound het	F	Norwegian	44	36	80	Y	Temporal cortex, locus coeruleus, parahippocampal cortex, substantia nigra	Early intermittent tremor in left hand, anosmia, later bradykinesia, rigidity, good response to L-dopa 300 mg/d, L-dopa induced severe dyskinesia, good response to deep brain stimulation (18 years post-onset), increased L-dopa to 1000 mg/d with minimal dyskinesia, treatment with anti-depressants	Y	Nybø et al., 2020¹¹⁷
Exon 7 del/c.1488 + 1G > A	Compound het	M	Spanish	31	8	39	Y	Reticular nuclei in the brainstem, Meynert nucleus, substantia nigra	Early pain and rigidity in left shoulder/arm, later rigidity in left leg, clumsiness in left limbs, gait impairment, postural instability, anxiety, very good response to L-dopa 200 mg/d and rasagiline 1 mg/d, increasingly strange behavior, isolation, severe psychosis, paranoid delirium of himself	Y	Samaranch et al., 2010*¹¹⁶
Leu347Pro	Hom	F	Chamorro	44	49	93	Y	Amygdala, minimal in the substantia nigra	Prominent and unusually bobbing of the head, diagnosis of ALS at 44 (also carried a heterozygous DNAJC13 mutation), very good response to L-dopa, mild forgetfulness	Y	Steele et al., 2015⁸⁶
Cys388Arg	Hom	F	Japanese	54	10	64	N	—	Rigidity, bradykinesia, small step, gait freezing, postural instability, foot dystonia, difficulty moving leg, all predominant on right side, very good response to dopamine agonist, irritability, auditory hallucination, insomnia, good response to L-dopa and decarboxylase, L-dopa induced dyskinesia and wearing off	Y	Takanashi et al., 2016¹²⁷

Environmental toxins are risk factors in combination with PINK1 variants

Environmental toxins like paraquat, rotenone, and manganese (found in insecticides, herbicides, and working in mining and steel mills) can cause oxidative stress, acceleration of motor deficits, and increased dopaminergic neuron desensitization and death in PINK1 PD in vitro and in vivo.^187–192 Five early-onset PINK1 heterozygotes in a population of Indian PD patients (with variants p.Arg246Gln (likely pathogenic) and p.Arg276Gln (uncertain significance)) were all described with additional marked and rare symptoms of lower limb pain, speech impairment, and impaired ocular movement.²⁴ Notably, these patients had overall poor responses to levodopa, which is in contrast to most PINK1 patients, and they were also exposed to environmental toxins for up to 25 years (pesticides, insecticides, or living in rural areas drinking water from a well).²⁴ Brazilian patients with a PINK1 single nucleotide polymorphism (IVS1−7A > G) who were exposed to environmental risk factors (rural living, drinking water from wells, or exposure to pesticides, insecticides, or organic solvents) had a lower age at disease onset compared to other EOPD patients, possibly via alterations to gene expression (as the polymorphism is located in the intronic region of PINK1).⁸² Different PINK1 variants exhibit different molecular effects, which can subsequently be exacerbated by environmental toxins, resulting in a significant risk factor.

A common but distinct PINK1 phenotype

Though the reports in our analysis varied greatly from detailed case studies to simple clinical notes, the 193 patients with symptom information presented similarly to past descriptions of PINK1-PD, exhibiting frequent occurrences of gait impairment (33.16%), often severe, indicating symptoms predominated in the lower limbs^6,8,9 (see Supplemental Information 5). Asymmetry of symptoms was observed in almost half of the patients (44.04%), and occurrences of early dystonia (12.44%) and psychiatric symptoms (up to 18.14%) were consistent with the literature.^1,2,7 PD patients with PINK1 variants may be more likely to develop psychiatric disturbances compared to those with idiopathic PD.^{6,94,95,105,114,193} As expected from previous reports,^6,7,9 most patients responded to L-dopa (74.09%) to a very good or excellent degree (23.78% of responders) with doses often around 300–600 mg daily, though predictably, many also presented with L-dopa-induced dyskinesia and motor complications (35.75% and 19.69%, respectively). It is suggested that PINK1 PD may have significantly higher rates of dyskinesia and motor fluctuations compared to other monogenic forms of EOPD.¹⁹⁴

Anosmia has been observed in a homozygous Filipino case of pathogenic p.Leu347Pro PINK1 PD,¹²⁰ four pathogenic p.Gln456Ter homozygotes (and seven heterozygotes) from a large German family,¹⁶⁷ and across several Italian families, in one likely pathogenic p.Ala168Pro homozygote and six pathogenic p.Trp437Ter homozygotes.¹²³ Of note was that eight unaffected carriers of heterozygous p.Ala168Pro or p.Trp437Ter from the same families also showed mild to moderate hyposmia at a pathologically significant level for their age, highlighting the importance of this symptom in early PD detection.¹²³

Sex and zygosity in the PINK1-PD symptom profile

Across the sex groups and zygosity groups, the mean years of disease duration appeared slightly longer for females compared to males (17.06 ± 1.32 years (n = 68) and 13.43 ± 1.13 years (n = 75), respectively) and homozygotes compared to heterozygotes (17.42 ± 1.13 years (n = 105) and 11.91 ± 1.05 (n = 57), respectively). Males, on average, appear more likely to receive a higher dose of L-dopa than females and may be more likely to receive more than one other course of treatment (see Supplemental Information 6). Additionally, they appear more likely to be reported with more severe depression or mood disturbance. Homozygotes may be more likely to present with gait impairment and dystonia compared to heterozygotes (see Supplemental Information 7). They may also receive a higher L-dopa dose than heterozygotes, which would be expected if homozygous disease is assumed to be more severe. These findings are novel, as previous PINK1 PD research either lacks the cohort size to perform any quantitative comparisons, or instead focuses broadly on the disease rather than any patient-specific differences.

However, it must be acknowledged that heterogeneity of reporting (likely omitting many symptoms) and a broad range in disease duration (0–47 years, likely changing over time) limit the definitive conclusions that can be drawn about symptomatology. Overall, this calls for more systematic reporting of patient symptom information and a shift in the perspective of PINK1 PD from a homogenous rare disorder to a multi-faceted spectrum of disease.

Age at onset: an intermediate phenotype for heterozygous PINK1?

PD-affected PINK1 heterozygotes are frequently described with higher ages of onset than PINK1 homozygotes and a phenotype akin to idiopathic PD.^{6,25,26,90–92,118} According to published literature, the mean age at onset for patients with homozygous PINK1 variants is 33 years,¹⁹⁵ compared to approximately 60–65 years for idiopathic PD.¹⁹⁶ Our systematic search found age at onset information for 216 patients with potentially pathogenic PINK1 variants (38.41 ± 0.91, mean ± SEM). The average age at onset for homozygous and compound heterozygous variants (n = 140) was 35.96 ± 1.12 years (mean ± SEM), while for heterozygous variants (n = 74) it was 43.36 ± 1.58 years (mean ± SEM) (Figure 3(c)). The mean age at onset for heterozygotes is still early-onset (<50 years of age), yet it is significantly older than the mean for homozygotes (Student's t-test, p = 0.0000930). This is consistent with the theory of an intermediary level of heterozygous disease between severe early-onset homozygotes and late-onset idiopathic patients, manifesting as a mixed PINK1-idiopathic phenotype.

Figure 3.
Meta-analysis of 192 PINK1 cases detailed in Table 1 stratified by zygosity, age of onset and sex. Cases with single point variants, by (a) amino acid position, and (b) gene region. Age at onset by (c) zygosity and, (d) sex. Age at onset by sex of variants reported in both sexes, for (e) homozygous variants, (f) heterozygous variants, (g) variants in the N-lobe of PINK1's kinase domain, (h) variants in the C-lobe of PINK1's kinase domain, n = males, females.

Females have earlier ages at onset than males

The overall mean age at onset for males (n = 99) was 39.71 ± 1.34 years and 35.5 ± 1.42 years for females (n = 90), with a statistically significant difference between sexes (Student's t-test, p = 0.0316) (Figure 3(d)).

To establish if PINK1 variant location is associated with age of onset and sex, we categorized the variants into protein regions in Figure 3(b) (excluding compound variants as they do not have a single location). We defined these as ‘early protein region’ (amino acids 1–155, comprised of the mitochondrial targeting sequence and other regulatory regions), N-lobe of the kinase domain (156–340), C-lobe of the kinase domain (341–511), and ‘late protein region’ (512–581) based on the varied lengths described in the literature.^{145,146,148–150} Of these variants, 86.98% lay within the kinase region (Figure 3(a) and (b)), reemphasizing the association of variants in this domain with disease.

Sex differences are dependent on zygosity and variant location

To further tease apart trends in sex differences, we averaged the ages at onset for the specific variants reported in both sexes (Figure 3(e)–(h)). Homozygous variants reported in both sexes showed females have significantly earlier ages at onset than males (paired t-test, p = 0.0362). Variants in the N-lobe of the PINK1 kinase domain also showed this pattern of significantly earlier onset ages for females compared to males (paired t-test, p = 0.0293). Six out of seven heterozygous variants showed a trend for lower ages of onset in females than males, though pairwise comparison was not significant (paired t-test, p = 0.234). Variants in the C-lobe show more variation and not as clear of a sex difference (paired t-test, p = 0.654).

Sex effects are different for PINK1-PD versus idiopathic PD

Sex effects have been established for general PD risk in previous literature, with the incidence of PD in males being 91% higher than females, most prominent after 60 years of age.¹⁹⁷ Males, in general, also have earlier onset ages than females.¹⁹⁸ However, little to no literature exists about the link between sex and PINK1 PD specifically. In PINK1-knockout rodents, downregulation of neurogenesis¹⁹⁹ and several hundred other genes occurred in both sexes, though there was some variance in gene type (genes involved in axon guidance, syntaxin, and ubiquitin were predominantly affected in male rats versus genes involved in sodium channel activity, calcium signaling, and synapse organization in females).²⁰⁰ In aged mice, PINK1 is upregulated with no apparent sex differences,²⁰¹ but in humans, PINK1 upregulation in the substantia nigra of PD patients is only observed in males.²⁰²

Though overall animal models suggest sex differences on a genomic level, there are always constraints to translating these data to humans. In our systematic search, we observed a similar incidence of males and females with PINK1 variants (140 males and 124 females over the whole cohort), though we identified a clear pattern of earlier age at onset for females compared to males, with further analyses suggesting zygosity of the variant and the location along the gene may also play a role. This finding is novel and of particular interest as the relationship is the inverse to that seen in idiopathic disease. Continued work to document additional PINK1 PD cases will enable the validation of this finding and the investigation of any other differences in clinical profiles.

α-Synuclein pathology is evident in PINK1 disease

The pathology of PINK1 PD is under debate, and due to a lack of extensive research, it is assumed that α-Syn is not implicated in the disease. However, this may be an incorrect assumption. Typical idiopathic PD pathology is characterized by misfolded and aggregated α-Syn proteins, which form toxic Lewy bodies that slowly spread throughout the brain,²⁰³ and changes in PINK1 may be related to α-Syn accumulation. α-Syn aggregates are present in PINK1-deficient rodents,²⁰⁴ and this absence of functional PINK1 increases vulnerability to α-Syn aggregation compared to control rodents.^205,206 The PINK1 protein is hypothesized to promote the degradation of excess α-Syn,²⁰⁷ and different variants in PINK1 may produce varying pathology. Amino acid deletion at position 245 of the protein (pathogenic), variant p.Leu347Pro (pathogenic), and variant p.Glu417Gly (likely pathogenic) in PINK1 cell cultures caused an increase in α-Syn aggregation,²⁰⁸ and notably, p.Gly309Asp (uncertain significance) completely abolished PINK1's interaction with α-Syn to initiate autophagy.²⁰⁷ Fibroblasts from patients with PINK1 p.Gly309Asp variants had increased α-Syn expression compared to controls, and this effect was replicated in control fibroblasts by knocking out PINK1, highlighting the importance of PINK1 in α-Syn degradation.²⁰⁹

α-Synuclein pathology in homozygous evidence

Though limited, the human post-mortem pathology of homozygous PINK1-affected brains points towards α-Syn involvement (Table 2). In a Norwegian case with over 30 years of disease duration, Lewy pathology was observed in the temporal cortex, locus coeruleus, parahippocampal cortex, and substantia nigra,¹¹⁷ while a younger Spanish case with eight years of disease duration before death at 39 years of age was positive for Lewy bodies in the reticular nuclei, Meynert nucleus, and substantia nigra.¹¹⁶ A case from Guam was diagnosed with PD at a surprisingly late age of 67 years, and postmortem observations found Lewy pathology only in the amygdala, in contrast to the previous reports where this region was spared.⁸⁶ However, this Guamanian patient was diagnosed with amyotrophic lateral sclerosis at 44 and also carried a heterozygous pathogenic DNAJC13 variant, so their results must be interpreted with caution.⁸⁶ The only record arguing for the absence of Lewy bodies in PINK1 PD describes a Japanese case with 10 years of disease duration and death at 64 years of age.¹²⁷ All three of these α-Syn-positive cases described had substantia nigra neuron loss and gliosis consistent with typical PD pathology.^86,116,117

Table 2.
Postmortem analyses of α-synuclein in PINK1-mutated Parkinson's disease cases.

Amino acid change Zygosity Sex Ethnicity Age at onset (years) Disease duration (years) Age at death (years) α-syn Location of a-synuclein Symptomatology Family history Reference

Ala339Thr Het M English 64 14 78 Y Brainstem, neocortex Early hypomimia, mild rigidity, tremor, later postural instability with frequent falls, very good L-dopa response, history of flat affect, cognitive decline after 7 years, rapid progression in 4 years N Gandhi et al., 2006¹¹⁸

Tyr431His Het F English 59 21 80 Y Brainstem, neocortex Tremor predominant, early bradykinesia, rigidity, very good response to L-dopa, L-dopa induced dyskinesia and ON/OFF fluctuations, depression N Gandhi et al., 2006¹¹⁸

Asn451Ser Het M English 58 10 68 Y Brainstem, neocortex Early hypomimia, bradykinesia, rigidity, minimal rest tremor, later postural instability, responded to L-dopa, L-dopa induced dyskinesia, depression N Gandhi et al., 2006¹¹⁸

Cys575Arg Het M English 64 7 71 Y Brainstem, neocortex Early shuffling gait, tremor, rigidity, later hypophonia, very good response to L-dopa, history of paranoia and anxiety, confusion, visual hallucination, paranoia, cognitive decline after 5 years N Gandhi et al., 2006¹¹⁸

Leu77Pro/exon 4–5 del Compound het F Norwegian 44 36 80 Y Temporal cortex, locus coeruleus, parahippocampal cortex, substantia nigra Early intermittent tremor in left hand, anosmia, later bradykinesia, rigidity, good response to L-dopa 300 mg/d, L-dopa induced severe dyskinesia, good response to deep brain stimulation (18 years post-onset), increased L-dopa to 1000 mg/d with minimal dyskinesia, treatment with anti-depressants Y Nybø et al., 2020¹¹⁷

Exon 7 del/c.1488 + 1G > A Compound het M Spanish 31 8 39 Y Reticular nuclei in the brainstem, Meynert nucleus, substantia nigra Early pain and rigidity in left shoulder/arm, later rigidity in left leg, clumsiness in left limbs, gait impairment, postural instability, anxiety, very good response to L-dopa 200 mg/d and rasagiline 1 mg/d, increasingly strange behavior, isolation, severe psychosis, paranoid delirium of himself Y Samaranch et al., 2010*¹¹⁶

Leu347Pro Hom F Chamorro 44 49 93 Y Amygdala, minimal in the substantia nigra Prominent and unusually bobbing of the head, diagnosis of ALS at 44 (also carried a heterozygous DNAJC13 mutation), very good response to L-dopa, mild forgetfulness Y Steele et al., 2015⁸⁶

Cys388Arg Hom F Japanese 54 10 64 N — Rigidity, bradykinesia, small step, gait freezing, postural instability, foot dystonia, difficulty moving leg, all predominant on right side, very good response to dopamine agonist, irritability, auditory hallucination, insomnia, good response to L-dopa and decarboxylase, L-dopa induced dyskinesia and wearing off Y Takanashi et al., 2016¹²⁷

Del: deletion; Het: heterozygous; Hom: homozygous; M: male; F: female; α-syn: alpha synuclein; Y: yes; N: no.

α-Synuclein pathology in heterozygous evidence

Four heterozygous PINK1 cases have been investigated post-mortem for Lewy bodies, and α-Syn pathology was present in the brainstem and cortex¹¹⁸ (Table 2). Though Lewy body pathology cannot be confirmed until after death, the diagnostic PD test¹²³ meta-iodobenzylguanidine (MIBG) myocardial scintigraphy assessing heart function is used as a proxy tool.²¹⁰ Decreased MIBG uptake reflects increased cardiac denervation, linked to subsequent sympathetic ganglia cell death and Lewy pathology.²¹¹ PINK1 heterozygotes may have a decreased MIBG uptake compared to PINK1 homozygotes, similar to levels seen in idiopathic PD patients.^90,124

α-Synuclein pathology in PINK1

Whether PINK1 PD causes α-Syn pathology to manifest or if pathology is a common effect regardless of PINK1 variants must be questioned. The pathology in the four heterozygote postmortem analyses was reported at similar levels to idiopathic PD cases.¹¹⁸ Thus, it is unclear whether PINK1-related pathology involves Lewy bodies or if PINK1 heterozygous variants are coincidental and the pathology reflects a typical idiopathic phenotype. One α-Syn-positive homozygous case (Table 2) had a short disease duration (8 years) and died at the age of 39, which suggests the observed pathology was not simply a result of expected age-related degeneration. An interconnected relationship between α-Syn proliferation and PINK1-dependent mitochondrial function has been observed via TNF-receptor-associated protein 1, which interacts with PINK1 in mitochondrial regulation and mitigating α-Syn toxicity.¹⁸⁵ As well as debating the role of α-Syn in PINK1 PD, the reverse has been investigated, i.e., the role of PINK1 in the formation of α-Syn. In post-mortem brain tissue from confirmed α-Syn-positive patients, the mutated PINK1 protein was found to be a component of glial cytoplasmic inclusions (in MSA) and Lewy pathology (in PD and dementia with Lewy bodies).²¹²

Overall, α-Syn pathology was observed across ages and several different PINK1 variants, suggesting aggregation is not a specific effect of a given variant. Based on the limited data, 87.5% of PINK1 PD showed a presence of α-Syn aggregation, implicating α-Syn in PINK1 PD and disease pathology.

Conclusion

PINK1 PD manifests with a distinct phenotype of lower limb symptoms, a long-term excellent response to L-dopa, and a markedly early age at onset in contrast to idiopathic PD. However, PINK1 shows evidence for the presence of α-Syn pathology in disease progression, which idiopathic PD typically also exhibits. Despite similar observed presentation of PINK1-mutated PD regardless of variant zygosity and patient sex, disease onset is earlier for homozygotes versus heterozygotes and females versus males, indicating a spectrum of phenotypes within PINK1 disease. This spectrum has yet to be fully explored, especially in geographic regions underrepresented in research such as Polynesia, where we observed the highest variant rates.

As PINK1 PD is early-onset and progresses slowly, the appropriate disease management should differ from those diagnosed with late-onset idiopathic disease. Yet, the approach to all PD, including PINK1 PD, is often the same, and genetic testing is not always commonplace. In continued testing, treating PINK1 disease as a ‘sub-disease’ within PD will help establish and develop distinct phenotypic profiles of each specific variant. This approach is crucial for improving care for these individuals who face long-term disease burdens, especially in disadvantaged places where healthcare research and access are most vital.

Supplemental Material

sj-docx-1-pkn-10.1177_1877718X241304814 - Supplemental material for Rethinking ‘rare’ PINK1 Parkinson's disease: A meta-analysis of geographical prevalence, phenotypic diversity, and α-synuclein pathology

Supplemental material, sj-docx-1-pkn-10.1177_1877718X241304814 for Rethinking ‘rare’ PINK1 Parkinson's disease: A meta-analysis of geographical prevalence, phenotypic diversity, and α-synuclein pathology by Eden Paige Yin and Birger Victor Dieriks in Journal of Parkinson's Disease

Supplemental Material

sj-xlsx-2-pkn-10.1177_1877718X241304814 - Supplemental material for Rethinking ‘rare’ PINK1 Parkinson's disease: A meta-analysis of geographical prevalence, phenotypic diversity, and α-synuclein pathology

Supplemental material, sj-xlsx-2-pkn-10.1177_1877718X241304814 for Rethinking ‘rare’ PINK1 Parkinson's disease: A meta-analysis of geographical prevalence, phenotypic diversity, and α-synuclein pathology by Eden Paige Yin and Birger Victor Dieriks in Journal of Parkinson's Disease

Supplemental Material

sj-xlsx-3-pkn-10.1177_1877718X241304814 - Supplemental material for Rethinking ‘rare’ PINK1 Parkinson's disease: A meta-analysis of geographical prevalence, phenotypic diversity, and α-synuclein pathology

Supplemental material, sj-xlsx-3-pkn-10.1177_1877718X241304814 for Rethinking ‘rare’ PINK1 Parkinson's disease: A meta-analysis of geographical prevalence, phenotypic diversity, and α-synuclein pathology by Eden Paige Yin and Birger Victor Dieriks in Journal of Parkinson's Disease

Supplemental Material

sj-xlsx-4-pkn-10.1177_1877718X241304814 - Supplemental material for Rethinking ‘rare’ PINK1 Parkinson's disease: A meta-analysis of geographical prevalence, phenotypic diversity, and α-synuclein pathology

Supplemental material, sj-xlsx-4-pkn-10.1177_1877718X241304814 for Rethinking ‘rare’ PINK1 Parkinson's disease: A meta-analysis of geographical prevalence, phenotypic diversity, and α-synuclein pathology by Eden Paige Yin and Birger Victor Dieriks in Journal of Parkinson's Disease

Supplemental Material

sj-xlsx-5-pkn-10.1177_1877718X241304814 - Supplemental material for Rethinking ‘rare’ PINK1 Parkinson's disease: A meta-analysis of geographical prevalence, phenotypic diversity, and α-synuclein pathology

Supplemental material, sj-xlsx-5-pkn-10.1177_1877718X241304814 for Rethinking ‘rare’ PINK1 Parkinson's disease: A meta-analysis of geographical prevalence, phenotypic diversity, and α-synuclein pathology by Eden Paige Yin and Birger Victor Dieriks in Journal of Parkinson's Disease

Supplemental Material

sj-xlsx-6-pkn-10.1177_1877718X241304814 - Supplemental material for Rethinking ‘rare’ PINK1 Parkinson's disease: A meta-analysis of geographical prevalence, phenotypic diversity, and α-synuclein pathology

Supplemental material, sj-xlsx-6-pkn-10.1177_1877718X241304814 for Rethinking ‘rare’ PINK1 Parkinson's disease: A meta-analysis of geographical prevalence, phenotypic diversity, and α-synuclein pathology by Eden Paige Yin and Birger Victor Dieriks in Journal of Parkinson's Disease

Supplemental Material

sj-xlsx-7-pkn-10.1177_1877718X241304814 - Supplemental material for Rethinking ‘rare’ PINK1 Parkinson's disease: A meta-analysis of geographical prevalence, phenotypic diversity, and α-synuclein pathology

Supplemental material, sj-xlsx-7-pkn-10.1177_1877718X241304814 for Rethinking ‘rare’ PINK1 Parkinson's disease: A meta-analysis of geographical prevalence, phenotypic diversity, and α-synuclein pathology by Eden Paige Yin and Birger Victor Dieriks in Journal of Parkinson's Disease

Footnotes

Acknowledgments

The authors acknowledge authors of studies included in the meta-analysis for their generous contributions of additional data: Dr Łukasz Milanowski, Dr Monika Rudzińska, Dr Joanna Suida, Dr Bruno Benitez, and Professor Christine Klein.

ORCID iD

Eden Paige Yin

Birger Victor Dieriks

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: EPY is funded through a University of Auckland Doctoral Scholarship. BVD is funded by a Health Research Council Hercus Fellowship (21/034), the School of Medical Science, the University of Auckland, and Te Tītoki Mataora (3729090 & 3729858). The funders had no role in study design, data collection and analysis, publication decisions, or manuscript preparation.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Data availability

The data supporting the findings of this study are available within the article and/or its supplemental material.

Supplemental material

Supplemental material for this article is available online.

References

1.
Al-Rumayyan A Klein C Alfadhel M . Early-onset parkinsonism: case report and review of the literature. Pediatr Neurol 2017; 67: 102–106.

2.
Klein C Westenberger A . Genetics of Parkinson’s disease. Cold Spring Harb Perspect Med 2012; 2: a008888.

3.
James SL Abate D Abate KH , et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet 2018; 392: 1789–1858.

4.
Ou Z Pan J Tang S , et al. Global trends in the incidence, prevalence, and years lived with disability of Parkinson’s disease in 204 countries/territories from 1990 to 2019. Front Public Health 2021; 9: e776847.

5.
Milanowski ŁM Lindemann JA Hoffman-Zacharska D , et al. Frequency of mutations in PRKN, PINK1, and DJ1 in patients with early-onset Parkinson disease from neighboring countries in Central Europe. Parkinsonism Relat Disord 2021; 86: 48–51.

6.
Bonifati V Rohe CF Breedveld GJ , et al. Early-onset parkinsonism associated with PINK1 mutations: frequency, genotypes, and phenotypes. Neurology 2005; 65: 87–95.

7.
Kasten M Hartmann C Hampf J , et al. Genotype-phenotype relations for the Parkinson’s disease genes parkin, PINK1, DJ1: MDSGene systematic review. Mov Disord 2018; 33: 730–741.

8.
Nuytemans K Theuns J Cruts M , et al. Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update. Hum Mutat 2010; 31: 763–780.

9.
Valente EM Salvi S Ialongo T , et al. PINK1 Mutations are associated with sporadic early-onset parkinsonism. Ann Neurol 2004; 56: 336–341.

10.
Klein C . Implications of genetics on the diagnosis and care of patients with Parkinson disease. Arch Neurol 2006; 63: 328–334.

11.
Rogaeva E Johnson J Lang AE , et al. Analysis of the PINK1 gene in a large cohort of cases with Parkinson disease. Arch Neurol 2004; 61: 1898–1904.

12.
Patel SG Buchanan CM Mulroy E , et al. Potential PINK1 founder effect in Polynesia causing early-onset Parkinson’s disease. Mov Disord 2021; 36: 2199–2200.

13.
Nishioka K Kefi M Jasinska-Myga B , et al. A comparative study of LRRK2, PINK1 and genetically undefined familial Parkinson’s disease. J Neurol Neurosurg Psychiatry 2009; 81: 391–395.

14.
Darvish H Movafagh A Omrani MD , et al. Detection of copy number changes in genes associated with Parkinson’s disease in Iranian patients. Neurosci Lett 2013; 551: 75–78.

15.
Hedrich K Hagenah J Djarmati A , et al. Clinical spectrum of homozygous and heterozygous PINK1 mutations in a large German family with Parkinson disease: role of a single hit? Arch Neurol 2006; 63: 833–838.

16.
Scornaienchi V Civitelli D De Marco EV , et al. Mutation analysis of the PINK1 gene in Southern Italian patients with early-and late-onset parkinsonism. Parkinsonism Relat Disord 2012; 18: 651–653.

17.
Camargos ST Dornas LO Momeni P , et al. Familial parkinsonism and early onset Parkinson’s disease in a Brazilian movement disorders clinic: phenotypic characterization and frequency of SNCA, PRKN, PINK1, and LRRK2 mutations. Mov Disord 2009; 24: 662–666.

18.
Kukkle PL Geetha TS Chaudhary R , et al. Genome-wide polygenic score predicts large number of high risk individuals in monogenic undiagnosed young onset Parkinson’s disease patients from India. Adv Biol 2022; 6: e2101326.

19.
Tan E-K Yew K Chua E , et al. PINK1 Mutations in sporadic early-onset Parkinson’s disease. Mov Disord 2006; 21: 789–793.

20.
Tay YW Tan AH Lim JL , et al. Genetic study of early-onset Parkinson’s disease in the Malaysian population. Parkinsonism Relat Disord 2023; 111: 105399.

21.
Yonova-Doing E Atadzhanov M Quadri M , et al. Analysis of LRRK2, SNCA, Parkin, PINK1, and DJ-1 in Zambian patients with Parkinson’s disease. Parkinsonism Relat Disord 2012; 18: 567–571.

22.
Wang F Feng X Ma J , et al. A common A340T variant in PINK1 gene associated with late-onset Parkinson’s disease in Chinese. Neurosci Lett 2006; 410: 121–125.

23.
Zhou Y Luo X Li F , et al. Association of Parkinson’s disease with six single nucleotide polymorphisms located in four PARK genes in the northern Han Chinese population. J Clin Neurosci 2012; 19: 1011–1015.

24.
Biswas A Sadhukhan T Majumder S , et al. Evaluation of PINK1 variants in Indian Parkinson’s disease patients. Parkinsonism Relat Disord 2010; 16: 167–171.

25.
Guo J Zhang X Nie L , et al. Mutation analysis of Parkin, PINK1 and DJ-1 genes in Chinese patients with sporadic early onset parkinsonism. J Neurol 2010; 257: 1170–1175.

26.
Toft M Myhre R Pielsticker L , et al. PINK1 Mutation heterozygosity and the risk of Parkinson’s disease. J Neurol Neurosurg Psychiatry 2007; 78: 82–84.

27.
Al-Mubarak BR Bohlega SA Alkhairallah TS , et al. Parkinson’s disease in Saudi patients: a genetic study. PLoS One 2015; 10: e0135950.

28.
Bandres-Ciga S Mencacci NE Duran R , et al. Analysis of the genetic variability in Parkinson’s disease from southern Spain. Neurobiol Aging 2016; 37: 210.e1–210.e5.

29.
Benitez BA Davis AA Jin SC , et al. Resequencing analysis of five Mendelian genes and the top genes from genome-wide association studies in Parkinson’s disease. Mol Neurodegener 2016; 11: 29.

30.
Cazeneuve C Sân C Ibrahim SA , et al. A new complex homozygous large rearrangement of the PINK1 gene in a Sudanese family with early onset Parkinson’s disease. Neurogenetics 2009; 10: 265–270.

31.
Chen H Jin Y-H Xue Y-Y , et al. Novel ATP13A2 and PINK1 variants identified in Chinese patients with Parkinson’s disease by whole-exome sequencing. Neurosci Lett 2020; 733: 135075.

32.
Choi JM Woo MS Ma H-I , et al. Analysis of PARK genes in a Korean cohort of early-onset Parkinson disease. Neurogenetics 2008; 9: 263–269.

33.
Diez-Fairen M Benitez BA Ortega-Cubero S , et al. Pooled-DNA target sequencing of Parkinson genes reveals novel phenotypic associations in Spanish population. Neurobiol Aging 2018; 70: 325.e1–325.e5.

34.
Erer S Egeli U Zarifoglu M , et al. Mutation analysis of the PARKIN, PINK1, DJ1, and SNCA genes in Turkish early-onset Parkinson’s patients and genotype-phenotype correlations. Clin Neurol Neurosurg 2016; 148: 147–153.

35.
Fung H-C Chen C-M Hardy J , et al. Analysis of the PINK1 gene in a cohort of patients with sporadic early-onset parkinsonism in Taiwan. Neurosci Lett 2006; 394: 33–36.

36.
Halder T Raj J Sharma V , et al. Novel P-TEN-induced putative kinase 1 (PINK1) variant in Indian Parkinson’s disease patient. Neurosci Lett 2015; 605: 29–33.

37.
Keyser RJ Lombard D Veikondis R , et al. Analysis of exon dosage using MLPA in South African Parkinson’s disease patients. Neurogenetics 2009; 11: 305–312.

38.
Keyser RJ Lesage S Brice A , et al. Assessing the prevalence of PINK1 genetic variants in South African patients diagnosed with early- and late-onset Parkinson’s disease. Biochem Biophys Res Commun 2010; 398: 125–129.

39.
Klein C Djarmati A Hedrich K , et al. PINK1, Parkin, and DJ-1 mutations in Italian patients with early-onset parkinsonism. Eur J Hum Genet 2005; 13: 1086–1093.

40.
Koziorowski D Hoffman-Zacharska D Sławek J , et al. Incidence of mutations in the PARK2, PINK1, PARK7 genes in Polish early-onset Parkinson disease patients. Neurol Neurochir Pol 2013; 47: 319–324.

41.
Lee M-J Mata IF Lin C-H , et al. Genotype-phenotype correlates in Taiwanese patients with early-onset recessive parkinsonism. Mov Disord 2009; 24: 104–108.

42.
Li N Wang L Zhang J , et al. Whole-exome sequencing in early-onset Parkinson’s disease among ethnic Chinese. Neurobiol Aging 2020; 90: 150.e5–150.e11.

43.
Li J Li N Wang L , et al. A compound heterozygous PINK1-associated juvenile Parkinson’s disease with pregnancy in Chinese. J Neurol 2021; 268: 2223–2227.

44.
Lim S-Y Ahmad-Annuar A Lohmann K , et al. Parkinson’s disease with homozygous PINK1 p.Leu489Pro mutations in two Indian sisters. Neurol Asia 2021; 26: 167–173.

45.
Lin C-H Chen P-L Tai C-H , et al. A clinical and genetic study of early-onset and familial parkinsonism in Taiwan: an integrated approach combining gene dosage analysis and next-generation sequencing. Mov Disord 2019; 34: 506–515.

46.
Lohmann E Dursun B Lesage S , et al. Genetic bases and phenotypes of autosomal recessive Parkinson disease in a Turkish population. Eur J Neurol 2012; 19: 769–775.

47.
Morales-Briceno H Ong TL Duma SR , et al. Recurrent biallelic p.L347P PINK1 variant in polynesians with parkinsonism and isolated dopa-responsive dystonia. Mov Disord Clin Pract 2022; 9: 696–697.

48.
Moura KCV Junior MC de Rosso ALZ , et al. Exon dosage variations in Brazilian patients with Parkinson’s disease: analysis of SNCA, PARKIN, PINK1 and DJ-1 genes. Dis Markers 2012; 32: 173–178.

49.
Norman BP Lubbe SJ Tan M , et al. Early onset Parkinson’s disease in a family of Moroccan origin caused by a p.A217D mutation in PINK1: a case report. BMC Neurol 2017; 17: 153.

50.
Smaoui S Boukhris A Lesage S , et al. Clinical and genetic characteristics of PINK1 mutation in Tunisian patients with Parkinson’s disease. Eur J Neurol 2012; 19: 735–735.

51.
Siuda J Jasinska-Myga B Boczarska-Jedynak M , et al. Early-onset Parkinson’s disease due to PINK1 p.Q456X mutation – clinical and functional study. Parkinsonism Relat Disord 2014; 20: 1274–1278.

52.
Tan MMX Malek N Lawton MA , et al. Genetic analysis of Mendelian mutations in a large UK population-based Parkinson’s disease study. Brain 2019; 142: 2828–2844.

53.
Tan AH Lohmann K Tay YW , et al. PINK1 P.Leu347Pro mutations in Malays: prevalence and illustrative cases. Parkinsonism Relat Disord 2020; 79: 34–39.

54.
Tejera-Parrado C Mir P Periñán MT , et al. A genetic analysis of a Spanish population with early onset Parkinson’s disease. PLoS One 2020; 15: e0238098.

55.
Tipton PW Jaramillo-Koupermann G Soto-Beasley AI , et al. Genetic characterization of Parkinson’s disease patients in Ecuador and Colombia. Parkinsonism Relat Disord 2020; 75: 27–29.

56.
Ton ND Thuan ND Thuong MTH , et al. Rare and novel variants of PRKN and PINK1 genes in Vietnamese patients with early-onset Parkinson’s disease. Mol Genet Genomic Med 2020; 8: e1463.

57.
Wang P Guo Y Song C , et al. PINK1 P.K520RfsX3 mutation identified in a Chinese family with early-onset Parkinson’s disease. Neurosci Lett 2018; 676: 98–102.

58.
Youn J Lee C Oh E , et al. Genetic variants of PARK genes in Korean patients with early-onset Parkinson’s disease. Neurobiol Aging 2019; 75: 224.e9–224.e15.

59.
Deutschlander AB Soto AI Ertekin-Taner N , et al. Genetic characterization of PD-related genes in African American patients using exome sequencing. Ann Neurol 2017; 82: S181–S182.

60.
Ibrahim EAA Albasher SA . PINK1 Type of early onset Parkinson’s disease (EOPD) in Sudanese patients, 2018. Sudan J Med Sci 2019; 14: 78–90.

61.
Keyser RJ Carr J Bardien S . The PINK1 gene: investigating South African Parkinson’s disease patients. Mov Disord 2010; 52: S501.

62.
van der Merwe C Carr J Glanzmann B , et al. Exonic rearrangements in the known Parkinson’s disease-causing genes are a rare cause of the disease in South African patients. Neurosci Lett 2016; 619: 168–171.

63.
Kim SY Seong MW Jeon BS , et al. Phase analysis identifies compound heterozygous deletions of the PARK2 gene in patients with early-onset Parkinson disease. Clin Genet 2012; 82: 77–82.

64.
Lin Y Zeng Y-F Cai N-Q , et al. Analysis of exon dosage using multiplex ligation-dependent probe amplification in Chinese patients with early-onset Parkinson’s disease. Eur Neurol 2019; 81: 246–253.

65.
Luo Q Yang X Yao Y , et al. T313m polymorphism of the PINK1 gene in Parkinson’s disease. Exp Ther Med 2014; 8: 286–290.

66.
Sadhukhan T Biswas A Das SK , et al. DJ-1 variants in Indian Parkinson’s disease patients. Dis Markers 2012; 33: 127–135.

67.
Zhang B Hu Z Yin X , et al. Mutation analysis of parkin and PINK1 genes in early-onset Parkinson’s disease in China. Neurosci Lett 2010; 477: 19–22.

68.
Zhao Y Qin L Pan H , et al. The role of genetics in Parkinson’s disease: a large cohort study in Chinese mainland population. Brain 2020; 143: 2220–2234.

69.
Bonato G Pilleri M Mainardi M , et al. Genetic characterization of Parkinson’s disease in a selected population from North-eastern Italy. Eur J Neurol 2020; 27: 641–642.

70.
Bozi M Papadimitriou D Antonellou R , et al. Genetic assessment of familial and early-onset Parkinson’s disease in a Greek population. Eur J Neurol 2014; 21: 963–968.

71.
Bras J Guerreiro R Ribeiro M , et al. Analysis of Parkinson disease patients from Portugal for mutations in SNCA, PRKN, PINK1 and LRRK2. BMC Neurol 2008; 8: 1.

72.
Clarimon J Eerola J Hellstrom O , et al. Assessment of PINK1 (PARK6) polymorphisms in Finnish PD. Neurobiol Aging 2006; 27: 906–907.

73.
Deng H Le WD Zhang X , et al. G309d and W437OPA PINK1 mutations in Caucasian Parkinson’s disease patients. Acta Neurol Scand 2005; 111: 351–352.

74.
Deng H Le W Shahed J , et al. Mutation analysis of the parkin and PINK1 genes in American Caucasian early-onset Parkinson disease families. Neurosci Lett 2008; 430: 18–22.

75.
Germer EL Imhoff S Vilariño-Güell C , et al. The role of rare coding variants in Parkinson’s disease GWAS loci. Front Neurol 2019; 10: 1284.

76.
Healy DG Abou-Sleiman PM Ahmadi KR , et al. The gene responsible for PARK6 Parkinson’s disease, PINK1, does not influence common forms of parkinsonism. Ann Neurol 2004; 56: 329–335.

77.
Kolarikova K Vodicka R Vrtel R , et al. High-throughput sequencing haplotype analysis indicates in LRRK2 gene a potential risk factor for endemic parkinsonism in Southeastern Moravia, Czech Republic. Life (Basel) 2022; 12: 121.

78.
Lesage S Lohmann E Tison F , et al. Rare heterozygous parkin variants in French early-onset Parkinson disease patients and controls. J Med Genet 2008; 45: 43–46.

79.
Ricciardi L Petrucci S Guidubaldi A , et al. Phenotypic variability of PINK1 expression: 12 Years’ clinical follow-up of two Italian families. Mov Disord 2014; 29: 1561–1566.

80.
Schlitter AM Kurz M Larsen JP , et al. Exclusion of PINK1 as candidate gene for the late-onset form of Parkinson’s disease in two European populations. J Negat Results Biomed 2005; 4: 10.

81.
Simon-Sanchez J Kilarski LL Nalls MA , et al. Cooperative genome-wide analysis shows increased homozygosity in early onset Parkinson’s disease. PLoS One 2012; 7: e28787.

82.
Godeiro Junior C de Carvalho Aguiar PM Felicio AC , et al. PINK1 Polymorphism IVS1-7 A -> G, exposure to environmental risk factors and anticipation of disease onset in Brazilian patients with early-onset Parkinson’s disease. Neurosci Lett 2010; 469: 155–158.

83.
Godeiro-Junior C de Carvalho-Aguiar PM Felício AC , et al. PINK1 Mutations in a Brazilian cohort of early-onset Parkinson’s disease patients. Mov Disord 2009; 24: 1693–1696.

84.
Moura KCV Campos Junior M de Rosso ALZ , et al. Genetic analysis of PARK2 and PINK1 genes in Brazilian patients with early-onset Parkinson’s disease. Dis Markers 2013; 35: 181–185.

85.
Torrealba-Acosta G Yu E Lobo-Prada T , et al. Clinical and genetic analysis of Costa Rican patients with Parkinson’s disease. Front Neurol 2021; 12: 656342.

86.
Steele JC Guella I Szu-Tu C , et al. Defining neurodegeneration on Guam by targeted genomic sequencing: guamanian ALS/PDC. Ann Neurol 2015; 77: 458–468.

87.
Leutenegger A-L Salih MAM Ibáñez P , et al. Juvenile-onset parkinsonism as a result of the first mutation in the adenosine triphosphate orientation domain of PINK1. Arch Neurol 2006; 63: 1257–1261.

88.
Myhre R Steinkjer S Stormyr A , et al. Significance of the parkin and PINK1 gene in Jordanian families with incidences of young-onset and juvenile parkinsonism. BMC Neurol 2008; 8: e47.

89.
Soudyab M Shariati M Esfehani RJ , et al. Whole-exome sequencing study of consanguineous Parkinson’s disease families and related phenotypes: report of twelve novel variants. J Mol Neurosci 2022; 72: 2486–2496.

90.
Kumazawa R Tomiyama H Li Y , et al. Mutation analysis of the PINK1 gene in 391 patients with Parkinson disease. Arch Neurol 2008; 65: 802–808.

91.
Ishihara-Paul L Hulihan MM Kachergus J , et al. PINK1 Mutations and parkinsonism. Neurology 2008; 71: 896–902.

92.
Marongiu R Ferraris A Ialongo T , et al. PINK1 Heterozygous rare variants: prevalence, significance and phenotypic spectrum. Hum Mutat 2008; 29: 565–565.

93.
Brooks J Ding J Simon-Sanchez J , et al. Parkin and PINK1 mutations in early-onset Parkinson’s disease: comprehensive screening in publicly available cases and control. J Med Genet 2009; 46: 375–381.

94.
Ephraty L Porat O Israeli D , et al. Neuropsychiatric and cognitive features in autosomal-recessive early parkinsonism due to PINK1 mutations. Mov Disord 2007; 22: 566–569.

95.
Ibáñez P Lesage S Lohmann E , et al. Mutational analysis of the PINK1 gene in early-onset parkinsonism in Europe and North Africa. Brain 2006; 129: 686–694.

96.
Bandla SS Srilekha A Karchalkar P , et al. A case report on a novel PINK1 gene mutation in a female with a neurodegenerative disorder. EMJ Neurol 2022; 10: 100–103.

97.
Ben El Haj R Regragui W Tazi-Ahnini R , et al. A novel homozygous p.L539F mutation identified in PINK1 gene in a Moroccan patient with parkinsonism. Biomed Res Int 2016; 2016: 3460234.

98.
Chen Y Yu S Zhang G , et al. The mutation spectrum of Parkinson-disease-related genes in early-onset Parkinson’s disease in ethnic Chinese. Eur J Neurol 2022; 29: 3218–3228.

99.
Chishti MA Bohlega S Ahmed M , et al. T313m PINK1 mutation in an extended highly consanguineous Saudi family with early-onset Parkinson disease. Arch Neurol 2006; 63: 1483.

100.
Cobb SA Wider C Ross OA , et al. GCH1 In early-onset Parkinson’s disease. Mov Disord 2009; 24: 2070–2075.

101.
Djarmati A Hedrich K Svetel M , et al. Heterozygous PINK1 mutations: a susceptibility factor for Parkinson disease? Mov Disord 2006; 21: 1526–1530.

102.
Gelmetti V Ferraris A Brusa L , et al. Late onset sporadic Parkinson’s disease caused by PINK1 mutations: clinical and functional study. Mov Disord 2008; 23: 881–885.

103.
Hatano Y Li Y Sato K , et al. Novel PINK1 mutations in early-onset parkinsonism. Ann Neurol 2004; 56: 424–427.

104.
Hua P Zhao Y Zeng Q , et al. Genetic analysis of patients with early-onset Parkinson’s disease in eastern China. Front Aging Neurosci 2022; 14: 849462.

105.
Li Y Tomiyama H Sato K , et al. Clinicogenetic study of PINK1 mutations in autosomal recessive early-onset parkinsonism. Neurology 2005; 64: 1955–1957.

106.
Macedo MG Verbaan D Fang Y , et al. Genotypic and phenotypic characteristics of Dutch patients with early onset Parkinson’s disease. Mov Disord 2009; 24: 196–203.

107.
Mellick GD Siebert GA Funayama M , et al. Screening PARK genes for mutations in early-onset Parkinson’s disease patients from Queensland, Australia. Parkinsonism Relat Disord 2009; 15: 105–109.

108.
Prestel J Gempel K Hauser TK , et al. Clinical and molecular characterisation of a Parkinson family with a novel PINK1 mutation. J Neurol 2008; 255: 643–648.

109.
Spataro N Roca-Umbert A Cervera-Carles L , et al. Detection of genomic rearrangements from targeted resequencing data in Parkinson’s disease patients. Mov Disord 2017; 32: 165–169.

110.
Weng Y-H Chou Y-HW Wu W-S , et al. PINK1 Mutation in Taiwanese early-onset parkinsonism: clinical, genetic, and dopamine transporter studies. J Neurol 2007; 254: 1347–1355.

111.
Wilkins EJ Rubio JP Kotschet KE , et al. A DNA resequencing array for genes involved in Parkinson’s disease. Parkinsonism Relat Disord 2012; 18: 386–390.

112.
Zadikoff C Rogaeva E Djarmati A , et al. Homozygous and heterozygous PINK1 mutations: considerations for diagnosis and care of Parkinson’s disease patients. Mov Disord 2006; 21: 875–879.

113.
Caritativo ECA Yu JRT Bautista JMP , et al. Genetic screening of Filipinos suspected with familial Parkinson’s disease: a pilot study. Parkinsonism Relat Disord 2023; 108: e105319.

114.
Criscuolo C Volpe G De Rosa A , et al. PINK1 Homozygous W437X mutation in a patient with apparent dominant transmission of parkinsonism. Mov Disord 2006; 21: 1265–1267.

115.
Valente EM Abou-Sleiman PM Caputo V , et al. Hereditary early-onset Parkinson’s disease caused by mutations in PINK1. Science 2004; 304: 1158–1160.

116.
Samaranch L Lorenzo-Betancor O Arbelo JM , et al. PINK1-linked Parkinsonism is associated with Lewy body pathology. Brain 2010; 133: 1128–1142.

117.
Nybø CJ Gustavsson EK Farrer MJ , et al. Neuropathological findings in PINK1-associated Parkinson’s disease. Parkinsonism Relat Disord 2020; 78: 105–108.

118.
Gandhi S Muqit MMK Stanyer L , et al. PINK1 Protein in normal human brain and Parkinson’s disease. Brain 2006; 129: 1720–1731.

119.
Hu J Waters CH Spiegelman D , et al. Gene-based burden analysis of damaging private variants in PRKN, PARK7 and PINK1 in Parkinson’s disease cohorts of European descent. Neurobiol Aging 2022; 119: 136–138.

120.
Doostzadeh J Tetrud JW Allen-Auerbach M , et al. Novel features in a patient homozygous for the L347P mutation in the PINK1 gene. Parkinsonism Relat Disord 2007; 13: 359–361.

121.
Abou-Sleiman PM Muqit MMK McDonald NQ , et al. A heterozygous effect for PINK1 mutations in Parkinson’s disease? Ann Neurol 2006; 60: 414–419.

122.
Puschmann A Fiesel FC Caulfield TR , et al. Heterozygous PINK1 p.G411S increases risk of Parkinson’s disease via a dominant-negative mechanism. Brain 2017; 140: 98–117.

123.
Ferraris A Ialongo T Passali GC , et al. Olfactory dysfunction in Parkinsonism caused by PINK1 mutations. Mov Disord 2009; 24: 2350–2357.

124.
Hayashida A Li Y Yoshino H , et al. The identified clinical features of Parkinson’s disease in homo-, heterozygous and digenic variants of PINK1. Neurobiol Aging 2021; 97: 146.e1–146.e13.

125.
Valente EM Bentivoglio AR Dixon PH , et al. Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36. Am J Hum Genet 2001; 68: 895–900.

126.
Ando M Fiesel FC Hudec R , et al. The PINK1 p.I368N mutation affects protein stability and ubiquitin kinase activity. Mol Neurodegener 2017; 12: 32.

127.
Takanashi M Li Y Hattori N . Absence of Lewy pathology associated with PINK1 homozygous mutation. Neurology 2016; 86: 2212–2213.

128.
United Nations Population Division, Statistical databases and publications from national statistical offices, Eurostat , et al. Population, total, https://data.worldbank.org/indicator/SP.POP.TOTL?_gl=1%2A11dbz17%2A_gcl_au%2AMTg2ODIxMzk5OS4xNzI1OTI5NjEw (2024, accessed 31 August 2024).

129.
Karczewski KJ Francioli LC Tiao G , et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 2020; 581: 434–443.

130.
Richter T Nestler-Parr S Babela R , et al. Rare disease terminology and definitions—A systematic global review: report of the ISPOR rare disease special interest group. Value Health 2015; 18: 906–914.

131.
Pugach I Hübner A Hung H , et al. Ancient DNA from Guam and the peopling of the pacific. Proc Natl Acad Sci U S A 2021; 118: e2022112118.

132.
Germain DP Jurca-Simina IE . Principles of human genetics and Mendelian inheritance. In: Burlina AP (ed.) Neurometabolic hereditary diseases of adults. Cham: Springer International Publishing, 2018, pp.1–28.

133.
Klein C Schlossmacher MG . The genetics of Parkinson disease: implications for neurological care. Nat Rev Neurol 2006; 2: 136–146.

134.
Cook L Schulze J Verbrugge J , et al. The commercial genetic testing landscape for Parkinson’s disease. Parkinsonism Relat Disord 2021; 92: 107–111.

135.
Gan-Or Z . Clinical genetic testing in Parkinson’s disease should become part of routine patient care. Brain 2024; 147: 2595–2597.

136.
Cook L Verbrugge J Schwantes-An T-H , et al. Parkinson’s disease variant detection and disclosure: pD GENEration, a North American study. Brain 2024; 147: 2668–2679.

137.
Junker J Lange LM Vollstedt E , et al. Team science approaches to unravel monogenic Parkinson’s disease on a global scale. Mov Disord 2024; 39: 1868–1873.

138.
Dekker MCJ Coulibaly T Bardien S , et al. Parkinson’s disease research on the African continent: obstacles and opportunities. Front Neurol 2020; 11: e512.

139.
Elsayed I Martinez-Carrasco A Cornejo-Olivas M , et al. Mapping the diverse and inclusive future of Parkinson’s disease genetics and its widespread impact. Genes 2021; 12: 1681.

140.
Mohamed W . Parkinson’s genetics research on underrepresented AfrAbia populations: current state and future prospects. Am J Neurodegener Dis 2023; 12: 23.

141.
Williams U Bandmann O Walker R . Parkinson’s disease in Sub-Saharan Africa: a review of epidemiology, genetics and access to care. J Mov Disord 2018; 11: 53–64.

142.
Deas E Plun-Favreau H Wood NW . PINK1 Function in health and disease. EMBO Mol Med 2009; 1: 152–165.

143.
Truban D Hou X Caulfield TR , et al. PINK1, Parkin, and mitochondrial quality control: what can we learn about Parkinson’s disease pathobiology? J Parkinsons Dis 2017; 7: 13–29.

144.
Pickrell AM Youle RJ . The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson’s disease. Neuron 2015; 85: 257–273.

145.
Ma KY Fokkens MR Van Laar T , et al. Systematic analysis of PINK1 variants of unknown significance shows intact mitophagy function for most variants. NPJ Parkinsons Dis 2021; 7: 113–113.

146.
Paysan-Lafosse T Blum M Chuguransky S , et al. Interpro in 2022. Nucleic Acids Res 2023; 51: D418–D427.

147.
The UniProt Consortium, Bateman A Martin M-J , et al. Uniprot: the universal protein knowledgebase in 2023. Nucleic Acids Res 2023; 51: D523–D531.

148.
Gonçalves FB Morais VA . PINK1: a bridge between mitochondria and Parkinson’s disease. Life 2021; 11: 371–371.

149.
Kumar A Tamjar J Waddell AD , et al. Structure of PINK1 and mechanisms of Parkinson’s disease-associated mutations. Elife 2017; 6: e29985.

150.
Quinn PMJ Moreira PI Ambrósio AF , et al. PINK1/PARKIN Signalling in neurodegeneration and neuroinflammation. Acta Neuropathol Commun 2020; 8: 189–189.

151.
Corti O Lesage S Brice A . What genetics tells us about the causes and mechanisms of Parkinson’s disease. Physiol Rev 2011; 91: 1161–1218.

152.
Funayama M Hattori N . Molecular genetics of PINK1. Brain Nerve 2007; 59: 831–838.

153.
Petit A Kawarai T Paitel E , et al. Wild-type PINK1 prevents basal and induced neuronal apoptosis, a protective effect abrogated by Parkinson disease-related mutations. J Biol Chem 2005; 280: 34025–34032.

154.
Grünewald A Gegg ME Taanman J-W , et al. Differential effects of PINK1 nonsense and missense mutations on mitochondrial function and morphology. Exp Neurol 2009; 219: 266–273.

155.
Amati F . S100a4 calcium binding protein is differently expressed in patients with early-onset Parkinson’s disease associated with PINK1 W437X and PARK2 gene mutations. FEBS J 2013; 280: 417–417.

156.
Klein C Lohmann-Hedrich K Rogaeva E , et al. Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurol 2007; 6: 652–662.

157.
Tan E-K Refai FS Siddique M , et al. Clinically reported heterozygous mutations in the PINK1 kinase domain exert a gene dosage effect. Hum Mutat 2009; 30: 1551–1557.

158.
Deutschbauer AM Jaramillo DF Proctor M , et al. Mechanisms of haploinsufficiency revealed by genome-wide profiling in yeast. Genetics 2005; 169: 1915–1925.

159.
Johnson AF Nguyen HT Veitia RA . Causes and effects of haploinsufficiency. Biol Rev 2019; 94: 1774–1785.

160.
Wall DP Fraser HB Hirsh AE . Detecting putative orthologs. Bioinformatics 2003; 19: 1710–1711.

161.
Morrill SA Amon A . Why haploinsufficiency persists. Proc Natl Acad Sci U S A 2019; 116: 11866–11871.

162.
Veitia RA . Exploring the etiology of haploinsufficiency. Bioessays 2002; 24: 175–184.

163.
Zug R . Developmental disorders caused by haploinsufficiency of transcriptional regulators: a perspective based on cell fate determination. Biol Open 2022; 11: bio058896.

164.
Hagenah JM Becker B Bruggemann N , et al. Transcranial sonography findings in a large family with homozygous and heterozygous PINK1 mutations. J Neurol Neurosurg Psychiatry 2008; 79: 1071–1074.

165.
Harris ZL Takahashi Y Miyajima H , et al. Aceruloplasminemia: molecular characterization of this disorder of iron metabolism. Proc Natl Acad Sci U S A 1995; 92: 2539–2543.

166.
Madeo G Schirinzi T Martella G , et al. PINK1 Heterozygous mutations induce subtle alterations in dopamine-dependent synaptic plasticity. Mov Disord 2014; 29: 41–53.

167.
Eggers C Schmidt A Hagenah J , et al. Progression of subtle motor signs in PINK1 mutation carriers with mild dopaminergic deficit. Neurology 2010; 74: 1798–1805.

168.
Khan NL Valente EM Bentivoglio AR , et al. Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: an ¹⁸ F-dopa PET study. Ann Neurol 2002; 52: 849–853.

169.
Binkofski F Reetz K Gaser C , et al. Morphometric fingerprint of asymptomatic Parkin and PINK1 mutation carriers in the basal ganglia. Neurology 2007; 69: 842–850.

170.
Van Nuenen BFL Weiss MM Bloem BR , et al. Heterozygous carriers of a Parkin or PINK1 mutation share a common functional endophenotype. Neurology 2009; 72: 1041–1047.

171.
Krohn L Grenn FP Makarious MB , et al. Comprehensive assessment of PINK1 variants in Parkinson’s disease. Neurobiol Aging 2020; 91: 168.e1–168.e5.

172.
Nalls MA Blauwendraat C Vallerga CL , et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson’s disease: a meta-analysis of genome-wide association studies. Lancet Neurol 2019; 18: 1091–1102.

173.
Liu S Sawada T Lee S , et al. Parkinson’s disease–associated kinase PINK1 regulates miro protein level and axonal transport of mitochondria. PLoS Genet 2012; 8: e1002537.

174.
Park J Lee SB Lee S , et al. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 2006; 441: 1157–1161.

175.
Vanhauwaert R Verstreken P . Flies with Parkinson’s disease. Exp Neurol 2015; 274: 42–51.

176.
Esposito G Vos M Vilain S , et al. Aconitase causes iron toxicity in Drosophila pink1 mutants. PLoS Genet 2013; 9: e1003478.

177.
Kim K Yim J . Glutathione S-transferase omega suppresses the defective phenotypes caused by PINK1 loss-of-function in Drosophila. Biochem Biophys Res Commun 2013; 437: 615–619.

178.
Klein P Muller-Rischart AK Motori E , et al. Ret rescues mitochondrial morphology and muscle degeneration of Drosophila Pink1 mutants. EMBO J 2014; 33: 341–355.

179.
Liu S Lu B . Reduction of protein translation and activation of autophagy protect against PINK1 pathogenesis in Drosophila melanogaster. PLoS Genet 2010; 6: e1001237.

180.
Thomas RE Andrews LA Burman JL , et al. PINK1-parkin Pathway activity is regulated by degradation of PINK1 in the mitochondrial matrix. PLoS Genet 2014; 10: e1004279.

181.
Vos M Esposito G Edirisinghe JN , et al. Vitamin K₂ is a mitochondrial electron carrier that rescues Pink1 deficiency. Science 2012; 336: 1306–1310.

182.
Wang D Qian L Xiong H , et al. Antioxidants protect PINK1-dependent dopaminergic neurons in Drosophila. Proc Natl Acad Sci U S A 2006; 103: 13520–13525.

183.
Wu Z Sawada T Shiba K , et al. Tricornered/NDR kinase signaling mediates PINK1-directed mitochondrial quality control and tissue maintenance. Genes Dev 2013; 27: 157–162.

184.
Yun J Puri R Yang H , et al. MUL1 Acts in parallel to the PINK1/parkin pathway in regulating mitofusin and compensates for loss of PINK1/parkin. Elife 2014; 3: e01958.

185.
Zhang L Karsten P Hamm S , et al. TRAP1 Rescues PINK1 loss-of-function phenotypes. Hum Mol Genet 2013; 22: 2829–2841.

186.
Zhu M Li X Tian X , et al. Mask loss-of-function rescues mitochondrial impairment and muscle degeneration of Drosophila pink1 and parkin mutants. Hum Mol Genet 2015; 24: 3272–3285.

187.
Bornhorst J Chakraborty S Meyer S , et al. The effects of pdr1, djr1.1 and pink1 loss in manganese-induced toxicity and the role of α-synuclein in C. elegans. Metallomics 2014; 6: 476–490.

188.
Gegg ME Cooper JM Schapira AHV , et al. Silencing of PINK1 expression affects mitochondrial DNA and oxidative phosphorylation in dopaminergic cells. PLoS One 2009; 4: e4756.

189.
Langley MR Ghaisas S Ay M , et al. Manganese exposure exacerbates progressive motor deficits and neurodegeneration in the MitoPark mouse model of Parkinson’s disease: relevance to gene and environment interactions in metal neurotoxicity. Neurotoxicology 2018; 64: 240–255.

190.
Oh C-K Sultan A Platzer J , et al. S-nitrosylation of PINK1 attenuates PINK1/parkin-dependent mitophagy in hiPSC-based Parkinson’s disease models. Cell Rep 2017; 21: 2171–2182.

191.
Wang H-L Chou A-H Wu A-S , et al. PARK6 PINK1 mutants are defective in maintaining mitochondrial membrane potential and inhibiting ROS formation of substantia nigra dopaminergic neurons. Biochim Biophys Acta 2011; 1812: 674–684.

192.
Zhou H Huang C Tong J , et al. Early exposure to paraquat sensitizes dopaminergic neurons to subsequent silencing of PINK1 gene expression in mice. Int J Biol Sci 2011; 7: 1180–1187.

193.
Steinlechner S Stahlberg J Volkel B , et al. Co-occurrence of affective and schizophrenia spectrum disorders with PINK1 mutations. J Neurol Neurosurg Psychiatry 2006; 78: 532–535.

194.
Lesage S Lunati A Houot M , et al. Characterization of recessive Parkinson disease in a large multicenter study. Ann Neurol 2020; 88: 843–850.

195.
Schneider SA Klein C . PINK1 type of young-onset Parkinson disease. GeneReviews® [Internet], https://www.ncbi.nlm.nih.gov/books/NBK26472/ (2018, accessed 21 January 2024).

196.
Samii A Nutt JG Ransom BR . Parkinson’s disease. Lancet 2004; 363: 1783–1793.

197.
Van Den Eeden SK Tanner CM Bernstein AL , et al. Incidence of Parkinson’s disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 2003; 157: 1015–1022.

198.
Hayes MT . Gender differences in Parkinson’s disease. In: O'Neal MA (ed.) Neurology and psychiatry of women. Cham: Springer International Publishing, 2019, pp. 213–217.

199.
Otero PA Fricklas G Nigam A , et al. Endogenous PTEN-induced kinase 1 regulates dendritic architecture and spinogenesis. J Neurosci 2022; 42: 7848–7860.

200.
Kelm-Nelson CA Gammie S . Gene expression within the periaqueductal gray is linked to vocal behavior and early-onset parkinsonism in Pink1 knockout rats. BMC Genomics 2020; 21: e625.

201.
Howell RD Dominguez-Lopez S Ocañas SR , et al. Female mice are resilient to age-related decline of substantia nigra dopamine neuron firing parameters. Neurobiol Aging 2020; 95: 195–204.

202.
Cantuti-Castelvetri I Keller-McGandy C Bouzou B , et al. Effects of gender on nigral gene expression and Parkinson disease. Neurobiol Dis 2007; 26: 606–614.

203.
Braak H Ghebremedhin E Rüb U , et al. Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res 2004; 318: 121–134.

204.
Creed RB Goldberg MS . Analysis of α-synuclein pathology in PINK1 knockout rat brains. Front Neurosci 2019; 12: 1034–1034.

205.
Creed RB Goldberg MS . Enhanced susceptibility of PINK1 knockout rats to α-synuclein fibrils. Neuroscience 2020; 437: 64–75.

206.
Oliveras-Salvá M Macchi F Coessens V , et al. Alpha-synuclein-induced neurodegeneration is exacerbated in PINK1 knockout mice. Neurobiol Aging 2014; 35: 2625–2636.

207.
Liu J Wang X Lu Y , et al. Pink1 interacts with α-synuclein and abrogates α-synuclein-induced neurotoxicity by activating autophagy. Cell Death Dis 2017; 8: e3056.

208.
Liu W Vives-Bauza C Acín-Peréz R , et al. PINK1 Defect causes mitochondrial dysfunction, proteasomal deficit and α-synuclein aggregation in cell culture models of Parkinson’s disease. PLoS One 2009; 4: e4597.

209.
Hoepken H-H Gispert S Azizov M , et al. Parkinson patient fibroblasts show increased alpha-synuclein expression. Exp Neurol 2008; 212: 307–313.

210.
Sakakibara R Tateno F Kishi M , et al. MIBG Myocardial scintigraphy in pre-motor Parkinson’s disease: a review. Parkinsonism Relat Disord 2014; 20: 267–273.

211.
Orimo S Amino T Itoh Y , et al. Cardiac sympathetic denervation precedes neuronal loss in the sympathetic ganglia in Lewy body disease. Acta Neuropathol 2005; 109: 583–588.

212.
Murakami T Moriwaki Y Kawarabayashi T , et al. PINK1, A gene product of PARK6, accumulates in -synucleinopathy brains. J Neurol Neurosurg Psychiatry 2007; 78: 653–654.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.11 MB

0.08 MB

0.05 MB

0.03 MB

0.06 MB

0.08 MB

Rethinking ‘rare’ PINK1 Parkinson's disease: A meta-analysis of geographical prevalence,phenotypic diversity,and α-synuclein pathology

Abstract

Plain language summary

Keywords

Introduction

Methods

Results and discussion

Populations with the highest PINK1 variant rates are overlooked

Altered patterns of PINK1 inheritance

Ethnic bias in PD research and diagnosis

Homozygous PINK1 variants are not all created equal: different effects on protein function influence overall PD risk

Function and structure of PINK1

Mechanisms of PINK1 pathogenesis

A spectrum of PINK1 pathogenicity

Potential heterozygous PINK1 insufficiency

Heterozygous PINK1 brains show significant but subclinical signs of disease

Heterozygous PINK1 variants do not cause PD (alone)

Other variants of mitochondria function influence PINK1 disease

Environmental toxins are risk factors in combination with PINK1 variants

A common but distinct PINK1 phenotype

Sex and zygosity in the PINK1-PD symptom profile

Age at onset: an intermediate phenotype for heterozygous PINK1?

Females have earlier ages at onset than males

Sex differences are dependent on zygosity and variant location

Sex effects are different for PINK1-PD versus idiopathic PD

α-Synuclein pathology is evident in PINK1 disease

α-Synuclein pathology in homozygous evidence

α-Synuclein pathology in heterozygous evidence

α-Synuclein pathology in PINK1

Conclusion

Supplemental Material

sj-docx-1-pkn-10.1177_1877718X241304814 - Supplemental material for Rethinking ‘rare’ PINK1 Parkinson's disease: A meta-analysis of geographical prevalence, phenotypic diversity, and α-synuclein pathology

Supplemental Material

sj-xlsx-2-pkn-10.1177_1877718X241304814 - Supplemental material for Rethinking ‘rare’ PINK1 Parkinson's disease: A meta-analysis of geographical prevalence, phenotypic diversity, and α-synuclein pathology

Supplemental Material

sj-xlsx-3-pkn-10.1177_1877718X241304814 - Supplemental material for Rethinking ‘rare’ PINK1 Parkinson's disease: A meta-analysis of geographical prevalence, phenotypic diversity, and α-synuclein pathology

Supplemental Material

sj-xlsx-4-pkn-10.1177_1877718X241304814 - Supplemental material for Rethinking ‘rare’ PINK1 Parkinson's disease: A meta-analysis of geographical prevalence, phenotypic diversity, and α-synuclein pathology

Supplemental Material

sj-xlsx-5-pkn-10.1177_1877718X241304814 - Supplemental material for Rethinking ‘rare’ PINK1 Parkinson's disease: A meta-analysis of geographical prevalence, phenotypic diversity, and α-synuclein pathology

Supplemental Material

sj-xlsx-6-pkn-10.1177_1877718X241304814 - Supplemental material for Rethinking ‘rare’ PINK1 Parkinson's disease: A meta-analysis of geographical prevalence, phenotypic diversity, and α-synuclein pathology

Supplemental Material

sj-xlsx-7-pkn-10.1177_1877718X241304814 - Supplemental material for Rethinking ‘rare’ PINK1 Parkinson's disease: A meta-analysis of geographical prevalence, phenotypic diversity, and α-synuclein pathology

Footnotes

Acknowledgments

ORCID iD

Funding

Declaration of conflicting interests

Data availability

Supplemental material

References

Supplementary Material